Clinical Trials News

Mon Jan 07, 2019 00:00

Clinical Trials Survey
Would you like to help improve the clinical research experience for patients? We are interested in your opinion about reporting your symptoms for clinical trials. Please click the link below to complete this short, 5-minute survey. Your anonymous responses will be used for research purposes to better understand how to improve patient care. Complete the survey and provide your email address to be entered to win a $100 Visa gift card! Thank you for taking the time to provide your opinion.

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Mon Jan 07, 2019 00:00

Schizophrenia – Princeton NJ
Do you or a loved one suffer from Schizophrenia? If so, Princeton Medical Institute located in Princeton, NJ is conducting a clinical research trial of an investigational treatment for Schizophrenia. We’re seeking volunteers 18 to 65 years old who have been diagnosed with Schizophrenia Study-related exams, procedures, and medication are provided at no cost. Visit our website to learn more and submit your interest! Common Symptoms of Schizophrenia May Include: Withdrawal from reality Hallucinations…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Sun Jan 06, 2019 00:00



Pediatric Plaque Psoriasis – Clearwater FL
Click image to enlargeLocal dermatologists are conducting a clinical research study to test the effectiveness and safety of an investigational topical medication for Plaque Psoriasis.Qualified Participants Must:Be 12-16 years old Provide consent and be accompanied by a legal guardian at the time of consent signing Have an Investigator’s Global Assessment (IGA) score of at least 3 Be willing to comply with all study instructions and commit to follow-up visits Females must not be pregnant and agree…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Fri Jan 04, 2019 00:00



<b>Eczema (Atopic Dermatitis) – Webster TX</b>
Click image to enlarge

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Thu Jan 03, 2019 00:00

<b>ADHD with Impulsive Aggression – Grand Prairie TX</b>
Aggression refers to a behavior that can result in both physical and psychological harm to oneself, others or objects in the environment. Aggression is manifested verbally, mentally, and physically. Such behavior becomes maladaptive when it persists, occurs outside an acceptable social context, and is of an intensity, frequency, severity and/or duration detrimental to the child’s interests. This is a double-blind, randomized, parallel group, two-arm, placebo-controlled study with flexible dosing…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Thu Jan 03, 2019 00:00

Osteoarthritis of the Knee – La Mesa CA
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee – Woodstock GA
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Excessive Underarm Sweating Study for Children – Raleigh NC
Does Your Child Struggle with Excessive Underarm Sweat?Consider Joining a Clinical Research Study of a New MedicationWake Research is enrolling participants in a study of an investigational medication for excessive underarm sweat in children and teens.

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee – Phoenix AZ
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Remove ads
Osteoarthritis of the Knee – Albuquerque NM
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee – Kansas City MO
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee – Carmichael CA
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee – Edgewater FL
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee – San Angelo TX
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee – Charleston SC
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

<b>Osteoarthritis of the Knee – Multiple Locations in the US</b>
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Osteoarthritis of the Knee – Cincinnati OH
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Alzheimer’s Disease – Spring Hill FL
If you are caring for someone with Alzheimer’s disease, please consider the ROAD clinical research study, which will determine the safety and effectiveness of the multifunctional small moleculeAD-35 in patients with mild to moderate Alzheimer’s disease (AD).Key Eligibility Criteria• Between 50 and 85 years of age (inclusive)• Diagnosed with probable AD in accordance with the National Institute on Aging and Alzheimer’s Association (NIA-AA) criteria• Mini-Mental State Examination (MMSE) score of ≥>…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Child ADHD – Lakeland FL
Is your child is experiencing the following symptoms: trouble staying focused, interrupts others, hyper or impulsive or does not listen, OR has already been diagnosed with Attention Deficit Hyperactivity Disorder (ADHD)? If yes, learn more about a medical research study evaluating an investigational study drug in children 6 to 17 years of age.

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 02, 2019 00:00

Data Highlighting Potential Benefits of Lm Platform Presented at 2019 Keystone Symposia Conference on Cancer Vaccines
PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that two presentations highlighting the potential of Advaxis vectors to generate T cell responses to a large percentage of neoantigens and to promote antigen spreading and potentially slow progression of prostate cancer, were presented at the 2019 Keystone Symposia on Cancer Vaccines, held January 19-24

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Fri Jan 25, 2019 15:05



Global PD-1 and PD-L1 Inhibitors Market 2019-2023 | Strong Pipeline to Boost Growth | Technavio
LONDON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Inhibitors?src=hash" target="_blank"gt;#Inhibitorslt;/agt;–The global PD-1 and PD-L1 Inhibitors market is expected to post a CAGR of over 19% during the period 2019-2023, according to Technavio.

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Fri Jan 25, 2019 14:00

Circassia to buy US, China marketing rights to AIT’s AirNOvent
The acquired rights will cover all potential indications in the hospital setting for the administration of inhaled AirNOvent at up to 80 parts per million. One of the The post Circassia to buy US, China marketing rights to AIT’s AirNOvent appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Fri Jan 25, 2019 08:54

Navitor Pharmaceuticals commences phase 1 clinical evaluation of NV-5138 for treatment-resistant depression
NV-5138 is a first-in-class, orally-active small molecule that directly activates mTORC1, the gatekeeper of cellular metabolism and renewal, which is suppressed in the brain of people suffering from The post Navitor Pharmaceuticals commences phase 1 clinical evaluation of NV-5138 for treatment-resistant depression appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Fri Jan 25, 2019 08:54

FDA accepts X-Rx’s IND application for X-165 to treat IPF
X-165 is a highly potent and selective small molecule inhibitor of Autotaxin owned by X-Rx. An initial advanced lead series that led to the identification of X-165 was The post FDA accepts X-Rx’s IND application for X-165 to treat IPF appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Fri Jan 25, 2019 08:54

EC approves Clovis’ Rubraca to treat women with relapsed ovarian cancer
The second indication of Rubraca has been approved as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer The post EC approves Clovis’ Rubraca to treat women with relapsed ovarian cancer appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Fri Jan 25, 2019 06:56



ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results
WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 8, 2019 to discuss its 2018 operating results. Management will also provide a brief update on the business. Conference Call InformationTo access the live call by phone, dial 323-794-2093; the conference ID is 6271602. The call may also be a

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 23:30

Immunomic to Present at the 2019 BIO CEO & Investor Conference
ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc. announced today that its’ founder and CEO, William Hearl, Ph.D., will present an overview of the company and its UNITE technology platform at the 2019 BIO CEO & Investor Conference on February 12, 2019 at 2:00 pm EST in the Hudson/Empire Room at the Marriott Marquis in New York City. About UNITE ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, is thought to work by encoding the Lysosomal Assoc

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 23:05

Vermont Collaborative Partners with Netsmart to Alter Trajectory of Care for State’s Most Vulnerable
OVERLAND PARK, Kan.–(BUSINESS WIRE)–Four member agencies of Vermont Care Partners (VCP) have come together to reshape the delivery and coordination of care through a partnership with Netsmart to deploy a unified technology platform. As value-based care quickly becomes reality, Lamoille County Mental Health Services, Northwestern Counseling and Support Services, United Counseling Services of Bennington and Washington County Mental Health Services will leverage the full suite of solutions from

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 22:00

Remove ads
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study
The treatment of patients with Bing-Neel syndrome (BNS) is not standardized. We included patients with Waldenström macroglobulinemia (WM) and a radiologic and/or cytologic diagnosis of BNS treated with ibrutinib monotherapy. Response assessment was based on criteria for BNS from the 8th International Workshop for WM. Survival from BNS diagnosis (BNS survival), survival from ibrutinib initiation to last follow-up or death (ibrutinib survival), and time from ibrutinib initiation to ibrutinib discontinuation…

www.bloodjournal.org?w=16&cs=1876081726

Blood CLINICAL TRIALS AND OBSERVATIONS

Thu Jan 24, 2019 19:00



Oyster Point Pharma to Present at the BIO CEO & Investor Conference
PRINCETON, N.J.–(BUSINESS WIRE)–Oyster Point Pharma to present a corporate overview at the BIO CEO & Investor Conference.

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 17:33



Midwest Vision Research Foundation at Pepose Vision Institute Joins the AcuFocus IC-8® Lens Clinical Study for Patients with Cataracts
ST. LOUIS, Mo.–(BUSINESS WIRE)–Midwest Vision Research Foundation at Pepose Vision Institute joins the AcuFocus IC-8® Lens clinical study for cataracts.

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 16:05

Tamr Joins Accenture’s Life Sciences Ecosystem to Help Drive Innovation in Drug Discovery and Scientific Research
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Tamr Inc. today announced it has joined Accenture’s open partner ecosystem, designed to help independent software vendors (ISVs) and life science companies team more effectively to accelerate drug discovery efforts and improve patient outcomes. The ecosystem is an integral part of Accenture’s cloud-based informatics research platform, which has been designed to help life sciences organizations improve productivity, efficiency, and innovation in drug discovery.

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 16:00

Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting
BOSTON–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;–Gamida Cell announces data from NAM-NK and NiCord® programs to be presented at 2019 TCT Annual Meeting

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 15:32



X-Rx Announces FDA Acceptance of IND Application for X-165
WALTHAM, Mass.–(BUSINESS WIRE)–X-Rx Announces FDA Acceptance of IND Application for X-165

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 15:15



Can-Fite BioPharma CEO Letter to Shareholders
PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that Pnina Fishman, Chief Executive Officer of Can-Fite Biopharma, has issued a Letter to Shareholders, the full text of which follows below. Dear Can-Fite Shareholders, It has been a very busy and productive year at Can Fite BioPharma, filled with c

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:30



Dicerna Evolves Its Board of Directors to Support Continued Growth
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna announced several changes to its board of directors, reflecting the company’s ongoing growth.

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:30



Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer
BURLINGTON, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24ARQL&src=ctag" target="_blank"gt;$ARQLlt;/agt; lt;a href="https://twitter.com/hashtag/arql?src=hash" target="_blank"gt;#arqllt;/agt;–ArQule, Inc.’s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®),…

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:00



Concert Pharmaceuticals Initiates Phase 1 Single-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia
LEXINGTON, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/CNCE?src=hash" target="_blank"gt;#CNCElt;/agt;–Concert began a Phase 1 single-ascending dose trial to evaluate the safety, tolerability, and PK profile of CTP 692 in healthy volunteers.

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:00



Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court
DUBLIN, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Ohio Supreme Court has dismissed a Petition filed by Capital Royalty Partners II, L.P. and affiliated entities. On August 27, 2018, Capital Royalty Partners II, L.P. and several affiliated entities ("CRG") filed a Petition with the Ohio Supreme Court seeking a

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 14:00



Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results
NEW YORK–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24BMY&src=ctag" target="_blank"gt;$BMYlt;/agt;–Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 13:59

BridgeBio Pharma raises $299.2m in financing round
BridgeBio Pharma will also use the funds to expand its efforts on the development of medicines for patients with unmet needs. Both existing investors KKR and Viking Global The post BridgeBio Pharma raises $299.2m in financing round appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Thu Jan 24, 2019 13:17

Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463
Data from the Phase 1 study are expected in the second half of 2019. “The initiation of this Phase 1 study with IW-6463 marks an important milestone for The post Ironwood Pharmaceuticals initiates phase 1 trial of IW-6463 appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Thu Jan 24, 2019 11:20

BioNTech to acquire MAB Discovery’s antibody generation unit
Under the terms of the agreement, BioNTech will acquire all assets, employees and proprietary know-how for mAb generation from MAB Discovery. MAB Discovery will retain ownership of and The post BioNTech to acquire MAB Discovery’s antibody generation unit appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Thu Jan 24, 2019 13:17



ChemoCentryx Announces Withdrawal of Phase II-Based Conditional Marketing Authorisation (CMA) Application for ANCA-Associated Vasculitis in Europe, Phase III Advocate Trial Data Release Planned for Q4 2019
ZURICH & MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Regulatory News: ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Ltd., a company of Vifor Pharma Group, today announced that in light of the upcoming availability of data from the pivotal Phase III ADVOCATE trial – the largest controlled trial in active anti-neutrophil cytoplasmic antibody associated vasculitis (ANCA-associated vasculitis) – they have decided to withdraw the application for Conditional Marketing Authorisation (CM

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 08:00

Gossamer Bio Announces Commencement of Initial Public Offering
SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the commencement of a proposed initial public offering of its common stock. Gossamer Bio is offering 14,375,000 sha

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Thu Jan 24, 2019 00:24

Advaxis’ Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests
PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced receipt of notification from the U.S. Food and Drug Administration (FDA) that the Company’s ongoing Phase 3, randomized, double-blinded, placebo-controlled, pivotal study of axalimogene filolisbac (AXAL) in high-risk, locally advanced cervical cancer (AIM2CERV) has been placed on partial clinical

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 23:05



Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers. IW-6463 is an orally administered central nervous system (CNS)-penetrant soluble guanylate cyclase (sGC) stimulator that is being developed for the treatment of serious and orphan CNS disorders. Data from the Phase 1 study are expected in the second half of 2019. “The initiation of this Phase 1 study with IW-6463 marks an im

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 23:01



Vedanta Biosciences Announces Publication in Nature of Seminal Research Revealing A New Mechanism of Human Microbiota-Driven Antitumor Immunity Involving Induction of IFNy+ CD8+ T Cell Accumulation in the Gut and Tumors
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vedanta Biosciences announced a publication in Nature that revealed a newly discovered mechanism underlying antitumor immunity.

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 20:07

Remove ads
Modulated Imaging Raises $7M in Series B Funding
IRVINE, Calif.–(BUSINESS WIRE)–Modulated Imaging has raised $7 million in Series B funding to fund the commercialization of its Clarifi technology and clinical studies.

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 19:30

Vascular Dynamics Names Prof. Martin Rothman Chief Medical Officer
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–World-renowned interventional cardiologist Martin Rothman has been named chief medical officer at VDI.

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 19:05

Redx gets regulatory nod to restart RXC004 clinical trial
An oral porcupine inhibitor, RXC004 has been designed to target the Wnt signaling pathway. The early-stage trial of the small molecule drug was temporarily stopped in March 2018 The post Redx gets regulatory nod to restart RXC004 clinical trial appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Wed Jan 23, 2019 17:43



U.S. Patent Office Issues CEL-SCI Two Patents for Its LEAPS Vaccine Platform Technology
VIENNA, Va.–(BUSINESS WIRE)–U.S. patent office issues CEL-SCI two patents for its LEAPS vaccine platform technology.

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 16:20



Medidata Joins the World Economic Forum
NEW YORK–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/MDSO?src=hash" target="_blank"gt;#MDSOlt;/agt;–Medidata (NASDAQ:MDSO) today announced that it has entered into a three-year strategic collaboration with the World Economic Forum. The company becomes a Partner Member Associate and will participate in the WEF System Initiative focused on Shaping the Future of Health and Healthcare. The initiative has a goal of transforming the continuum of care – from prevention to diagnosis, treatment,…

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:30



Ferring Pharmaceuticals appoints Sophie Opdyke to lead its new U.S. oncology division
PARSIPPANY, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Ferring?src=hash" target="_blank"gt;#Ferringlt;/agt;–Sophie Opdyke, Pharm.D., MBA, will be responsible for building the Ferring Pharmaceuticals (U.S.) oncology division

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:25



InGeneron Expands Development Pipeline with Two Osteoarthritis Programs
HOUSTON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/backpain?src=hash" target="_blank"gt;#backpainlt;/agt;–InGeneron expands development pipeline with two studies for chronic backpain and wrist osteoarthritis, setting focus on orthopedic indications.

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:00

BridgeBio Pharma Closes $299.2 Million Financing Round to Support Its Efforts to Target Genetic Disease at the Source
PALO ALTO, Calif.–(BUSINESS WIRE)–BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million. The round was co-led by existing investors KKR and Viking Global Investors. Other existing investors participating included Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Hercules Capital; and they were joined by new investors Sequoia Capital, and a blue-chip long-term investor. The financing wil

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 15:00



Talee Bio Announces $4.5 Million Award from the Cystic Fibrosis Foundation to Advance Development of Two Gene Therapy Product Candidates
PHILADELPHIA–(BUSINESS WIRE)–Talee Bio, Inc., a development stage biopharmaceutical company focused on developing gene therapy treatments for cystic fibrosis, today announced agreements with the Cystic Fibrosis Foundation (CF Foundation) to fund the preclinical development of two mutation-agnostic gene therapy product candidates, TL-101 and TL-102. The CF Foundation committed up to $4.5 million to expedite the development of both product candidates for all people with cystic fibrosis, and par

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 14:00

Sage Therapeutics Appoints Elizabeth Barrett and George Golumbeski to Board of Directors
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Elizabeth (Liz) Barrett and George Golumbeski, Ph.D., to the company’s board of directors. “We are extremely pleased to add these two experienced executives to Sage’s board of directors. As Sage continues to advance its programs in development, adding an executive

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 14:00



Triumvira Announces Build out of Senior Management Team with Addition of Industry-Experienced Professionals in R&D and Business Development
AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira appoints Andreas Bader as Senior Vice President of Research & Development and Joshua Carle as Vice President of Business Development.

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 14:00



New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model
LOS ANGELES–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Breastfeeding?src=hash" target="_blank"gt;#Breastfeedinglt;/agt;–Supplementation with unique B3 vitamin nicotinamide riboside confers significant and enduring physiological benefits to mouse mothers and offspring.

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 13:30



Idiopathic Pulmonary Fibrosis Report – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019-2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The "Idiopathic Pulmonary Fibrosis – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" drug pipelines has been added to ResearchAndMarkets.com’s offering. Idiopathic Pulmonary Fibrosis – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Idiopathic Pulmonary Fibrosis . The report includes information of marketed products including their product des

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Wed Jan 23, 2019 13:24

EC approves Blincyto in patients with Philadelphia chromosome negative minimal residual disease-positive B-cell precursor ALL
The approval was based on data from the Phase 2 BLAST study in frontline and relapsed/refractory ALL, the largest prospective trial for MRD-positive ALL ever conducted. BLINCYTO, a The post EC approves Blincyto in patients with Philadelphia chromosome negative minimal residual disease-positive B-cell precursor ALL appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Wed Jan 23, 2019 11:52

Rocket Pharmaceuticals announces clearance of IND for RP-A501 gene therapy for Danon disease
RP-A501 is the Company’s first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease that is in development under a collaboration with the University of The post Rocket Pharmaceuticals announces clearance of IND for RP-A501 gene therapy for Danon disease appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Wed Jan 23, 2019 11:52

GSK closes acquisition of Tesaro for $5.1bn
Tesaro acquisition will enable GSK to strengthen its pharmaceutical business; and expand its pipeline and commercial capability in oncology. Tesaro president and COO Dr Mary Lynne Hedley said: The post GSK closes acquisition of Tesaro for $5.1bn appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Wed Jan 23, 2019 11:52

UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
NEW YORK–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it intends to offer and sell $150 million of its ordinary shares in an underwritten public offering. The company also intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of ordinary shares sold in the offering at the pu

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 23:01



LabCorp Named to FORTUNE Magazine’s 2019 List of ‘World’s Most Admired Companies,’ Making the Annual List for the Second Consecutive Year
BURLINGTON, N.C.–(BUSINESS WIRE)–LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to FORTUNE magazine’s 2019 List of World’s Most Admired Companies, making the annual list for the second consecutive year. The annual survey, conducted by FORTUNE and Korn Ferry, a global organizational consulting firm, is given to top executives, directors, and financial analysts to identify the companies that enjoy the strongest reputations within their indust

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 17:35

Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration
BOSTON & MINNEAPOLIS–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;–Gamida Cell and Be The Match BioTherapies® announced a collaboration to improve outcomes for patients undergoing bone marrow transplantation.

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:30



Bio-Thera Solutions Announces Initiation of Phase III Clinical Trial for BAT1806, a Proposed Biosimilar of Actemra® (Tocilizumab)
GUANGZHOU, China–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/arthritis?src=hash" target="_blank"gt;#arthritislt;/agt;–Bio-Thera Solutions announces the initiation of a Phase III clinical trial for BAT1806, a proposed biosimilar of Actemra® (Tocilizumab).

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:08

Remove ads


LabConnect Announces Global Sample Processing Network
SEATTLE–(BUSINESS WIRE)–LabConnect is pleased to announce a new service: LabConnect’s global sample processing network (GSPN).

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:00



Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 7, 2019 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thursday, February 7, 20191:30 p.m. Pacific Time / 4

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:00

Rainier Therapeutics Announces Oral Abstract Presentation on Fierce 21 Phase 2 Trial of Vofatamab in Metastatic Urothelial Cell Carcinoma (Bladder Cancer) at the 2019 ASCO Genitourinary Cancers Symposium
SAN LEANDRO, Calif.–(BUSINESS WIRE)–Data from ongoing P2 trial of Rainier’s FGFR3-targeted antibody vofatamab to be presented at 2019 ASCO Genitourinary Cancers Symposium Feb 14 in SF

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 15:00



Resumen: Gore presenta en Europa la endoprótesis para aorta torácica adaptable GORE® TAG® con perfiles reducidos
FLAGSTAFF, Arizona–(BUSINESS WIRE)–W. L. Gore & Associates, Inc. (Gore) ha introducido hoy perfiles reducidos para los diámetros más utilizados de la endoprótesis para aorta torácica adaptable GORE® TAG® con el sistema de CONTROL ACTIVO. El perfil reducido permite a los médicos realizar reparaciones endovasculares torácicas (TEVAR) en pacientes con vasos más pequeños donde el acceso es difícil y la anatomía aórtica es tortuosa, lo que amplía la disponibilidad de la endoprótesis para aorta

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:47



Samenvatting: Gore introduceert GORE® TAG® Conformable Thoracic Stent Graft met gereduceerde profielen in Europa
FLAGSTAFF, Ariz.–(BUSINESS WIRE)–W. L. Gore & Associates, Inc. (Gore) introduceerde vandaag gereduceerde profielen voor de meest gebruikte diameters van de GORE® TAG® Conformable Thoracic Stent Graft met ACTIVE CONTROL System. Het gereduceerde profiel stelt artsen in staat om TEVAR uit te voeren bij patiënten met kleinere vaten waar de toegang moeilijk is en de aorta anatomie kronkelig is, waardoor de beschikbaarheid van Gore’s thoracale stenttransplantaat wordt uitgebreid naar een groter

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:47



Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease
WILMINGTON, Del.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24INCY&src=ctag" target="_blank"gt;$INCYlt;/agt;–Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:30



Data Presented at LINC Confirm the Safety and Effectiveness of Zilver® PTX®
BLOOMINGTON, Ind.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/cookmedical?src=hash" target="_blank"gt;#cookmedicallt;/agt;–Today at the Leipzig Interventional Course (LINC), Cook Medical participated in significant discussion about the use of paclitaxel to treat patients suffering from PAD. Through several presentations to meeting attendees, data supported the use of paclitaxel-coated devices to help the more than 200 million1 patients globally who are fighting the disease. “We believe…

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:10



Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive results for its exploratory Phase 2 head-to-head study evaluating the efficacy, safety and tolerability of voclosporin ophthalmic solution (VOS 0.2%) versus Restasis®(cyclosporine ophthalmic emulsion 0.05%) for the treatment of dry eye syndrome (DES). Both drugs were shown to be well-tolerate

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:00



Concert Pharmaceuticals Completes Enrollment of 12 mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata
LEXINGTON, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/AlopeciaAreata?src=hash" target="_blank"gt;#AlopeciaAreatalt;/agt;–Concert completed enrollment in its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata.

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:00

Immunochina Raises $20.4 Million USD in Series C Financing
BEIJING–(BUSINESS WIRE)–Beijing-based Immunochina Pharmaceuticals today announced the closing of its $140 million RMB Series C financing (approximately $20.4 million in US Dollars). This financing will enable the company to expand its GMP-grade manufacturing capabilities while continuing clinical trials for its lead IM19 product targeting B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Non Hodgkin’s Lymphoma, as well as advancing the development of its pipeline targeting multiple solid and li

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 14:00



Aplastic Anemia – Pipeline Insight, 2019 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The "Aplastic Anemia – Pipeline Insight, 2019" drug pipelines report has been added to ResearchAndMarkets.com’s offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Aplastic Anemia development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, assoc

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 13:40



Cluster Headache Syndrome – Pipeline Insight, 2019 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The "Cluster Headache Syndrome – Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com’s offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Cluster Headache Syndrome development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 13:34



TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products
GLASGOW, Scotland–(BUSINESS WIRE)–TC BioPharm (TCB), a developer of CAR-T immuno-oncology products, including Gamma Delta T (GDT) cell therapies, today announced it has completed formulation of its first allogeneic GDT cell banks. The T cell banks provide TCB with core technology to develop a deep portfolio of next-generation CAR-T products directed against a wide variety of different cancer types, both hematological and solid tumors. The project was supported by funding from the European Uni

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 12:55

Rationale and study design of the MyHEART study: A young adult hypertension self-management randomized controlled trial
Publication date: Available online 21 January 2019Source: Contemporary Clinical TrialsAuthor(s): Heather M. Johnson, Lisa Sullivan-Vedder, KyungMann Kim, Patrick E. McBride, Maureen A. Smith, Jamie N. LaMantia, Jennifer T. Fink, Megan R. Knutson Sinaise, Laura M. Zeller, Diane R. LauverAbstractYoung adults (18–39 year-olds) with hypertension have a higher lifetime risk for cardiovascular disease. However, less than 50% of young adults achieve hypertension control in the United States. Hypertension…

www.sciencedirect.com?w=16&cs=1235559972

ScienceDirect Publication: Contemporary Clinical Trials

Tue Jan 22, 2019 13:13

EC approves Vertex’s CF treatment Orkambi for children aged two to five years
The label extension has been granted to treat the most common form of CF based on data from a phase 3 open-label safety study in 60 patients. According The post EC approves Vertex’s CF treatment Orkambi for children aged two to five years appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Tue Jan 22, 2019 12:25

Nash’s NASH NP-160 shows repeated positive results in second pre-clinical study
In addition, a second compound, NP-135 was identified as an additional lead. Both NP-135 and NP-160 are one of a number of already approved compounds that Nash has The post Nash’s NASH NP-160 shows repeated positive results in second pre-clinical study appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Tue Jan 22, 2019 12:25



Global Clinical Trials 2007-2018: Current Trends and Recent Advancements – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The "Global Clinical Trials – Current Trends and Recent Advancement" report has been added to ResearchAndMarkets.com’s offering. "Global Clinical Trials Current Trends and Recent Advancement", provides an in-depth assessment of the current trends in the number of clinical trials globally, Top 10 therapy area, geography wise clinical trials, YOY clinical trials in top 10 therapy area. An overview of clinical guidelines reforms has also been provided to show how regulator

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 11:17



PredictImmune Confirms Canadian Patent Grant
CAMBRIDGE, England–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/IBD?src=hash" target="_blank"gt;#IBDlt;/agt;–PredictImmune confirm Canadian patent grant which covers PredictImmune’s intellectual property relating to methods for predicting autoimmune disease

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 11:00

PCI announces further investment in infrastructure for packaging of controlled substances
PCI has extended onsite controlled substance storage at its US commercial packaging locations in Philadelphia, PA and Rockford, IL, and will undertake further expansions as demand increases for The post PCI announces further investment in infrastructure for packaging of controlled substances appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Tue Jan 22, 2019 12:25

Remove ads


Wren Therapeutics Completes £18 Million Series A Financing
CAMBRIDGE, United Kingdom–(BUSINESS WIRE)–Wren Therapeutics (“Wren”), a biopharmaceutical company focused on drug discovery and development for protein misfolding diseases, today announces it has completed a Series A financing round. The company, formally founded in 2016, raised a total of £18 million from an international syndicate led by The Baupost Group with participation from LifeForce Capital and a number of high net worth individual investors. Protein molecules form the machinery that

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 09:30



EMMAC Life Sciences PLC: Acquisition of a Majority Interest in Medalchemy, a GMP Certified Laboratory, in Alicante Spain
LONDON–(BUSINESS WIRE)–EMMAC, the European independent medical cannabis company, is pleased to announce the acquisition of a majority interest in Medalchemy, a fully-licensed GMP certified laboratory in Alicante, Spain. Medalchemy, a technology-based manufacturing company located on the premises of the University of Alicante, has more than a decade of experience in the research, development and manufacture of active pharmaceutical ingredients (APIs) and has submitted license applications to i

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 09:00



Updated Analysis of Pivotal Study Reveals: Proactive, High Dosage of Venofer® Significantly Reduces Risk of Death or Major Cardiovascular Events in Haemodialysis Patients
ZURICH–(BUSINESS WIRE)–Re-analysis of pivotal study reveals: Proactive, High DOSAGE OF venofer®…

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 08:00



Ferring, Rebiotix and Karolinska Institutet Extend Collaboration to Research Next Generation of Microbiome Treatments
SAINT-PREX, Switzerland–(BUSINESS WIRE)–Ferring Pharmaceuticals and Karolinska Institutet announced today a five-year extension of their collaboration to explore the potential of the human microbiome in reproductive medicine and women’s health and gastroenterology. The collaboration brings together specialist expertise from Karolinska Institutet in early stage research, Rebiotix Inc. (acquired by Ferring in 2018), a late-stage clinical microbiome company, and Ferring’s therapeutic area and co

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Tue Jan 22, 2019 08:00

Proteus Digital Health Launches Digital Oncology Medicines to Improve Patient Outcomes
January 17, 2019 – REDWOOD CITY, Calif. and MINNEAPOLIS, Minn. – Proteus Digital Health®, Inc., Fairview Health Services, and University of Minnesota Health announced today that for the first time cancer patients are using digital…

www.drugs.com?w=16&cs=174197327

Drugs.com – Clinical Trials

Thu Jan 17, 2019 22:01

Two Positive Phase III studies of Tafenoquine for the Radical Cure of Plasmodium vivax Malaria Published in The New England Journal of Medicine
London UK; Philadelphia US; Geneva Switzerland – January 16, 2019 — GSK and Medicines for Malaria Venture (MMV) today announced the publication of positive results from two phase III studies of single-dose tafenoquine for the radical cure…

www.drugs.com?w=16&cs=174197327

Drugs.com – Clinical Trials

Wed Jan 16, 2019 23:01

vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study
HIGH POINT, N.C.–(BUSINESS WIRE)–Jan. 16, 2019– vTv Therapeutics Inc. (Nasdaq: VTVT) today announced the publication of a paper in Science Translational Medicine showcasing the discovery and development of TTP399, an investigational, oral, small…

www.drugs.com?w=16&cs=174197327

Drugs.com – Clinical Trials

Wed Jan 16, 2019 22:01

Amgen Makes All Repatha (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price
THOUSAND OAKS, Calif., Jan. 7, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that as part of the Company’s commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at…

www.drugs.com?w=16&cs=174197327

Drugs.com – Clinical Trials

Mon Jan 07, 2019 22:01



Gore führt GORE® TAG® Conformable Thoracic Stent Graft mit reduzierten Profilen für die Vermarktung in Europa ein
FLAGSTAFF, Arizona–(BUSINESS WIRE)–W. L. Gore & Associates, Inc. (Gore) meldete heute die Markteinführung reduzierter Profile für die am häufigsten verwendeten Durchmesser von GORE® TAG® Conformable Thoracic Stent Graft mit ACTIVE CONTROL System. Das reduzierte Profil ermöglicht es den Ärzten, bei Patienten mit kleineren Blutgefäßen eine thorakale endovaskuläre Aortenreparatur (TEVAR) durchzuführen, wenn der Zugang anspruchsvoll und die Aorta gewunden ist, um auf diese Weise die Einsatzmö

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 22:37



Gore lance sur le marché européen GORE® TAG®, une endoprothèse thoracique conformable à profils réduits
FLAGSTAFF, Arizona–(BUSINESS WIRE)–W. L. Gore & Associates, Inc. (Gore) a présenté aujourd’hui des profils réduits des diamètres les plus couramment utilisés de l’endoprothèse thoracique conformable implantable GORE® TAG® dotée du système ACTIVE CONTROL. La réduction du profil permet aux médecins de procéder à une procédure TEVAR (réparation endovasculaire des anévrismes de l’aorte thoracique) chez les patients dont les vaisseaux sont étroits et difficiles d’accès et l’anatomie aortique t

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 19:30



Riassunto: Gore lancia in Europa lo stent graft toracico conformabile GORE® TAG® con profili ridotti
FLAGSTAFF, Ariz.–(BUSINESS WIRE)–W. L. Gore & Associates, Inc. (Gore) ha oggi lanciato profili ridotti per i diametri più comunemente utilizzati dello stent graft toracico conformabile GORE® TAG® con sistema ACTIVE CONTROL. Il profilo ridotto consente al personale medico di eseguire trattamenti endovascolari dell’aorta toracica (TEVAR) nei pazienti con vasi sanguigni più piccoli, di difficile accesso e con anatomia aortica tortuosa, ampliando la disponibilità dello stent graft toracico di

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 16:18



Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 14:00



Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease
LONDON–(BUSINESS WIRE)–Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. “Today’s approval by the European Commission brings us one step closer to our goal of bringing treatment to all people living with CF,” said Reshma K

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 11:00



Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe
FLAGSTAFF, Ariz.–(BUSINESS WIRE)–Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 10:00

Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting Glutamatergic mechanism
Promentis is developing SXC-2023 along with other compounds that engage System xc-, a central nervous system target addressing glutamatergic imbalance and oxidative stress, to treat trichotillomania and other The post Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting Glutamatergic mechanism appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Mon Jan 21, 2019 12:58

Kyn Therapeutics, Celgene partner on immuno-oncology therapies development
The collaboration will combine the immuno-oncology expertise and pipeline of Kyn Therapeutics with the capabilities of Celgene in development and commercialization of drugs in areas of high unmet The post Kyn Therapeutics, Celgene partner on immuno-oncology therapies development appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Mon Jan 21, 2019 09:02

Lilly’s second immune-oncology candidate using Zymeworks’ Azymetric platform to start clinical trials
In accordance with Zymeworks’ 2014 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$8.0 million for Lilly’s submission of an IND application for The post Lilly’s second immune-oncology candidate using Zymeworks’ Azymetric platform to start clinical trials appeared first on Pharmaceutical Business review.

clinicaltrials.pharmaceutical-business-review.com?w=16&cs=3151548292

PBR – Clinical Trials News

Mon Jan 21, 2019 12:58



SanBio: Addition of a Cerebral Hemorrhage Program for SB623 Regenerative Cell Medicine
TOKYO–(BUSINESS WIRE)–At a meeting held today, the Board of Directors of SanBio Co., Ltd. (hereinafter, the “Company”) resolved to add a program for treatment of chronic motor deficit from cerebral hemorrhage as a new indication for SB623, a regenerative cell medicine developed by the Group. (Hereinafter, the “Group” refers to two companies, SanBio Co., Ltd., and SanBio, Inc.) 1. Details of the Decision As part of its mission to introduce new therapeutic drugs for the central nervous system,

www.businesswire.com?w=16&cs=3925733045

Business Wire Health: Clinical Trials News

Mon Jan 21, 2019 02:05

Design of a randomized trial testing a multi-level weight-control intervention to reduce obesity and related health conditions in low-income workers
Publication date: Available online 19 January 2019Source: Contemporary Clinical TrialsAuthor(s): Richard I. Stein, Jaime R. Strickland, Rachel G. Tabak, Ann Marie Dale, Graham A. Colditz, Bradley A. EvanoffAbstractWeight-control is a major public health focus for preventing multiple obesity-related health conditions. While clinic-based intensive lifestyle interventions are successful, low-socioeconomic-status (SES) populations, which have a higher burden of obesity, are difficult to reach; thus,…

www.sciencedirect.com?w=16&cs=1235559972

ScienceDirect Publication: Contemporary Clinical Trials

Sun Jan 20, 2019 13:44

Clinical Trials News

New Clinical Trials

2018 Peer Reviewers
Clinical Trials, Volume 16, Issue 1, Page 106-107, February 2019.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Tue Jan 22, 2019 05:52

Corrigendum
Clinical Trials, Ahead of Print.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Thu Jan 17, 2019 03:57

Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework
Clinical Trials, Ahead of Print.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Wed Jan 16, 2019 12:07

Editorial: We may need large trials to find treatments for neurodegenerative diseases
Clinical Trials, Ahead of Print.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Thu Jan 10, 2019 03:06

Conducting clinical trials—costs, impacts, and the value of clinical trials networks: A scoping review
Clinical Trials, Ahead of Print.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Thu Jan 10, 2019 03:06

Making the case for completion bonuses in clinical trials
Clinical Trials, Ahead of Print.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Thu Dec 20, 2018 11:46

Response to Chappell
Clinical Trials, Ahead of Print.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Wed Dec 19, 2018 11:32

Variance prior specification for a basket trial design using Bayesian hierarchical modeling
Clinical Trials, Ahead of Print.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Fri Dec 07, 2018 04:24

Commentary on Hay et al.: Can clinical trials data collection be improved by administrative data elements?
Clinical Trials, Volume 16, Issue 1, Page 18-19, February 2019.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Fri Nov 23, 2018 08:29

Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomes
Clinical Trials, Volume 16, Issue 1, Page 14-17, February 2019.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Fri Nov 23, 2018 08:26

Routinely collected data for trialists: The need for continued conversations and solution sharing
Clinical Trials, Ahead of Print.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Sat Nov 17, 2018 08:12

Automated safety event monitoring using electronic medical records in a clinical trial setting: Validation study using the VA NEPHRON-D trial
Clinical Trials, Volume 16, Issue 1, Page 81-89, February 2019.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Sat Nov 17, 2018 08:09

FDA-Catalyst—Using FDA’s Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial
Clinical Trials, Volume 16, Issue 1, Page 90-97, February 2019.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Sat Nov 17, 2018 08:08

Beware of on-treatment safety analyses
Clinical Trials, Volume 16, Issue 1, Page 63-70, February 2019.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Sat Nov 17, 2018 08:01

Conditional estimation and inference to address observed covariate imbalance in randomized clinical trials
Clinical Trials, Ahead of Print.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Fri Nov 16, 2018 12:52

Strategic inclusion of regions in multiregional clinical trials
Clinical Trials, Volume 16, Issue 1, Page 98-105, February 2019.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Fri Nov 16, 2018 12:51

The development of an end-to-end service solution to support lupus patients and improve their experience in clinical trials
Clinical Trials, Volume 16, Issue 1, Page 71-80, February 2019.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Thu Nov 15, 2018 07:18

Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease
Clinical Trials, Volume 16, Issue 1, Page 20-31, February 2019.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Wed Nov 14, 2018 14:27

Commentary on Diamond et al.: The efficiency of single institutional review board review in National Institute of Child Health and Human Development Cooperative Reproductive Medicine Network–initiated clinical trials
Clinical Trials, Volume 16, Issue 1, Page 11-13, February 2019.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Fri Oct 26, 2018 09:23

The efficiency of single institutional review board review in National Institute of Child Health and Human Development Cooperative Reproductive Medicine Network–initiated clinical trials
Clinical Trials, Volume 16, Issue 1, Page 3-10, February 2019.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Wed Oct 24, 2018 05:49

Generalizing the per-protocol treatment effect: The case of ACTG A5095
Clinical Trials, Volume 16, Issue 1, Page 52-62, February 2019.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Wed Oct 17, 2018 11:36

Comment on Vickers et al.
Clinical Trials, Ahead of Print.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Sat Oct 13, 2018 15:13

Shift models for dose-finding in partially ordered groups
Clinical Trials, Volume 16, Issue 1, Page 32-40, February 2019.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Fri Oct 12, 2018 08:26

A readily available improvement over method of moments for intra-cluster correlation estimation in the context of cluster randomized trials and fitting a GEE–type marginal model for binary outcomes
Clinical Trials, Volume 16, Issue 1, Page 41-51, February 2019.

journals.sagepub.com?w=16&cs=2616495262

SAGE Publications: Clinical Trials: Table of Contents

Mon Oct 08, 2018 04:11



Flu (Influenza) – Houston TX
Click image to enlargeCenters for Disease Control and Prevention (CDC) reports:· Flu is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and sometimes the lungs· Each year, on average, 5 % to 20 % of the U.S. population gets the flu· You may be able to pass on flu to someone else before you know you are sick, as well as while you are sickA clinical trial testing the effectiveness of an investigational medication for the flu is now…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Fri Jan 25, 2019 00:00



Flu (Influenza) – Meridian ID
Click image to enlargeCenters for Disease Control and Prevention (CDC) reports:· Flu is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and sometimes the lungs· Each year, on average, 5 % to 20 % of the U.S. population gets the flu· You may be able to pass on flu to someone else before you know you are sick, as well as while you are sickA clinical trial testing the effectiveness of an investigational medication for the flu is now…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Fri Jan 25, 2019 00:00



Chronic Spontaneous Urticaria – Clearwater FL
Click image to enlargeLocal dermatologists are conducting a clinical research study to test the effectiveness and safety of an investigational injected medication for Chronic Spontaneous Urticaria.

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Fri Jan 25, 2019 00:00

Asthma – Raleigh NC
Calling all young people with ASTHMA!Everyone’s asthma is different, so new treatments are always needed. Doctors need people like you to join a new research study, to test a new investigational asthma treatment. Can you help us? The RESPO Study for children with asthma * Is your child aged 5-17?* Have they had symptoms consistent with an asthma diagnosis for at least 6 months?* Are they accustomed to using an inhaler?

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Thu Jan 24, 2019 00:00



Primary Mitochondrial Myopathy – Atlanta GA
Click image to enlargeLocal doctors are seeking participants for a clinical research study to test the effectiveness and safety of an investigational product delivered through a pen injector to treat Primary Mitochondrial Myopathy. If you or a loved one has been diagnosed with PMM, you may qualify to participate.

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Thu Jan 24, 2019 00:00



Eczema – Norfolk VA
Click image to enlargeLocal doctors are recruiting volunteers for a clinical trial to evaluate the effectiveness of an investigational oral medication for moderate to severe atopic dermatitis (eczema). Take control of your health options and consider participating!

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 23, 2019 00:00

Osteoarthritis of the Knee – Miami FL
Clinical Research Study for Osteoarthritis of the Knee Are you or a loved one living with Osteoarthritis of the Knee, and seeking care options? You may be eligible to participate in a clinical research study, evaluating the safety and effectiveness of a new investigational medication, and receive study related care at no cost! See If You Or A Loved One Qualify!Participation Requirements You or a Loved One May Qualify If You Are between 40-80 years old Have been diagnosed with Osteoarthritis…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 23, 2019 00:00



Depression – Jamaica NY
Click image to enlarge

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Tue Jan 22, 2019 00:00

Treatment Resistant Depression – Middleburg Heights OH
To evaluate the efficacy, safety, and tolerability of cariprazine 1.5 mg/day and 3 mg/daycompared with placebo as an adjunctive to antidepressant therapy (ADT) in patients with major depressivedisorder (MDD) who have had an inadequate response to antidepressants alone

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Tue Jan 22, 2019 00:00

Depression – Cherry Hill NJ
Depression…It interferes with the ability to work, sleep, eat and enjoy life. If you are experiencing symptoms of depression, a clinical research study may be your next step.

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Mon Jan 21, 2019 00:00



Flu (Influenza) – West Palm Beach CA
Click image to enlargeCenters for Disease Control and Prevention (CDC) reports:· Flu is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and sometimes the lungs· Each year, on average, 5 % to 20 % of the U.S. population gets the flu· You may be able to pass on flu to someone else before you know you are sick, as well as while you are sickA clinical trial testing the effectiveness of an investigational medication for the flu is now…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Mon Jan 21, 2019 00:00

Anxiety – Cherry Hill NJ
Are you often worried, tense stressed, nervous, fearful or overly concerned? Always worrying about the what-ifs? If you are an adult experiencing symptoms of ANXIETY, you may be interested in participating in a clinical research study.

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Mon Jan 21, 2019 00:00

At Risk for Developing Symptoms of Alzheimer’s Disease – Sherman Oaks CA
California Neuroscience Research is conducting a research study of an investigational medication vs. placebo (an inactive substance) in participants who are between 60 and 75 and at increased risk for developing symptoms of Alzheimer’s Disease. Participation is voluntary.Participant has one office visit (+ phone follow-ups) for genetic testing. For those that are at increased risk of developing Alzheimer’s Disease and meet other inclusion and exclusion criteria, there can be up to 8 years of treatment…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Mon Jan 21, 2019 00:00

Type 1 Diabetes – Chattanooga TN
Living with Type 1 Diabetes?Consider the Gazelle StudyIf you are an adult between ages 18 and 65 living with type 1 diabetes, you may be eligible to take part in the GAZELLE clinical research trial. This trial will look at an investigational fast-acting insulin to see if it works as effectively as an existing fast-acting insulin already being used to treat diabetes.

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Mon Jan 21, 2019 00:00

Remove ads
Pediatric Major Depression – Lauderdale Lakes FL
Research study needs children and adolescents struggling with Major Depressive DisorderIf you’re struggling with Major Depressive Disorder (MDD), you may qualify for the Allergan clinical research study enrolling now. Local doctors are looking for children and adolescents male and female ages 7-17 who struggle with Major Depressive Disorder.

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Sun Jan 20, 2019 00:00

Crohn’s Disease – Southfield MI
Do you or a loved one suffer from Crohn’s Disease?What is Crohn’s Disease? Crohn’s disease is a type of inflammatory bowel disease or IBD that may affect any part of the gastrointestinal tract from mouth to the end of the digestive tract. Signs and symptoms often include abdominal pain, diarrhea (which may be bloody if inflammation is severe), fever, and weight loss. Other complications may occur outside the gastrointestinal tract and include anemia, skin rashes, arthritis, inflammation of the…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Thu Jan 17, 2019 00:00



Cancer, Obesity/Overweight and Insomnia (COIN) Study – Baltimore MD
Click image to enlargeFLYERVolunteers are needed for a research study assessing the effectiveness of a sleep intervention prior to a web- and phone-based weight loss program. The study involves 6 in-person visits and approximately 18 phone/videosessions over an 8-month period.

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Thu Jan 17, 2019 00:00



Flu (Influenza) – Carrollton TX
Click image to enlargeCenters for Disease Control and Prevention (CDC) reports:· Flu is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and sometimes the lungs· Each year, on average, 5 % to 20 % of the U.S. population gets the flu· You may be able to pass on flu to someone else before you know you are sick, as well as while you are sickA clinical trial testing the effectiveness of an investigational medication for the flu is now…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 16, 2019 00:00



Flu (Influenza) – Plano TX
Click image to enlargeCenters for Disease Control and Prevention (CDC) reports:· Flu is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and sometimes the lungs· Each year, on average, 5 % to 20 % of the U.S. population gets the flu· You may be able to pass on flu to someone else before you know you are sick, as well as while you are sickA clinical trial testing the effectiveness of an investigational medication for the flu is now…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 16, 2019 00:00

Moderate to Severe Facial Acne – Raleigh NC
Facial Acne StudyDo you have facial acne?You may be a candidate for our clinical research study!We are currently enrolling qualified participants in a clinical research study for an investigational topical gel.To see if you or someone you know may qualify, contact us today!

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 16, 2019 00:00



Flu (Influenza) – Austin TX
Click image to enlargeCenters for Disease Control and Prevention (CDC) reports:· Flu is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and sometimes the lungs· Each year, on average, 5 % to 20 % of the U.S. population gets the flu· You may be able to pass on flu to someone else before you know you are sick, as well as while you are sickA clinical trial testing the effectiveness of an investigational medication for the flu is now…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 16, 2019 00:00

Episodic Migraine Headaches – San Diego CA
Unhappy with the Pain and Inconvenience of Episodic Migraine Headaches?Consider Joining a Study of a Proposed New Type of Medicine.We’re enrolling participants in a study of the safety and tolerability of an investigational medication for people with episodic migraine headaches.Qualified participants must:Be age 18-80Have a 1+ year history of migraines starting before age 50Have 4-14 migraines or probable migraines a month, on average, in the three months prior to joining the study

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 16, 2019 00:00



Type 1 Diabetes – Escondido CA
Click image to enlargeLocal doctors are conducting a clinical trial to test the effectiveness of an investigational liver-selective glucokinase activator for management of Type 1 Diabetes.

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Wed Jan 16, 2019 00:00

Healthy Volunteers – Flu Test Study – Fayetteville NC
Are you interested in participating in a research study of an investigational test to detect the flu?You or your child may qualify if you are experiencing symptoms of the flu.

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Tue Jan 15, 2019 00:00

Healthy Volunteers – Flu Test Study – San Diego CA
Flu Test Clinical Trial Participants WantedAre you interested in participating in a research study of an investigational test to detect the flu?You or your child may qualify if you are experiencing symptoms of the flu.

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Tue Jan 15, 2019 00:00

Depression – Oceanside CA
Is depression affecting your quality of life? Excell Research is seeking volunteers living with depression to participate in a local research study. You may qualify if you: Are between the ages of 18-75 years old Are currently taking an anti-depressant for at least 4 weeks with little to no improvement in symptoms Have tried an antidepressant (for at least 4 weeks) in the last 18 months with little to no improvement in symptoms Have been experiencing a depressive episode for 8 weeks or longer…

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Tue Jan 15, 2019 00:00

Healthy Volunteers – Flu Test Study – Chattanooga TN
Are you interested in participating in a research study of an investigational test to detect the flu?You or your child may qualify if you are experiencing symptoms of the flu.

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Tue Jan 15, 2019 00:00

Healthy Volunteers – Flu Test – Raleigh NC
Flu Test Clinical Trial Participants WantedYou or your child may qualify if you are experiencing symptoms of the flu.Flu Test Clinical Times:Thursday, Jan. 17 at 9:00 AM, 11:00 AM, 1:00 PMWeekly afterward:Monday, Wednesday, Friday at 9:00 AM, 11:00 AM, 1:00 PM

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

Tue Jan 15, 2019 00:00

Migraine – Prairie Village KS
If you suffer with migraines and have between 4-14 migraines a month

www.clinicalconnection.com?w=16&cs=2003410936

ClinicalConnection.com New Clinical Trials

New Clinical Trials

ClinicalTrials


clinicaltrials.gov?w=16&cs=1163777504 ClinicalTrials

Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC
Conditions: Metastatic Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell CarcinomaIntervention: Drug: PembrolizumabSponsors: University College, London; Merck Sharp & Dohme Corp.Not yet recruiting

ClinicalTrials

1d

Bevacizumab and Pembrolizumab Combination in EBER-ISH Positive NPC
Conditions: Locally Recurrent Cancer; Metastatic Nasopharyngeal CancerInterventions: Drug: pembrolizumab; Drug: bevacizumabSponsors: National University Hospital, Singapore; Merck Sharp & Dohme Corp.Not yet recruiting

ClinicalTrials

1d

the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma
Condition: Lymph Node MetastasesIntervention: Procedure: lymph node dissectionSponsor: Zhejiang UniversityNot yet recruiting

ClinicalTrials

1d

Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma
Condition: Lymph Node MetastasesIntervention: Procedure: lymph node dissectionSponsor: Zhejiang UniversityNot yet recruiting

ClinicalTrials

1d

N-Force Screws Augmented With N-Force Blue in Hip Fractures
Conditions: Intracapsular Proximal Femur Fracture; Garden Grade I Subcapital Fracture of Femoral Neck; Garden Grade II Subcapital Fracture of Femoral NeckIntervention: Device: N-Force Screws Augmented with N-Force BlueSponsor: Zimmer BiometNot yet recruiting

ClinicalTrials

1d

ClinicalTrials

Otolaryngology


link.springer.com?w=16&cs=2673937404 Journal of the Association for Research in Otolaryngology

Neural Switch Asymmetry in Feature-Based Auditory Attention Tasks
Abstract Active listening involves dynamically switching attention between competing talkers and is essential to following conversations in everyday environments. Previous investigations in human listeners have examined the neural mechanisms that support switching auditory attention within the acoustic featural cues of pitch and auditory space. Here, we explored the cortical circuitry underlying endogenous switching of auditory attention between pitch and spatial cues necessary…

Journal of the Association for Research in Otolaryngology

18h

Mark above section as read

www.sciencedirect.com?w=16&cs=1235559972 Otorhinolaryngology

Hypereosinophilic syndrome presenting with bilateral ear fullness
Publication date: Available online 23 January 2019Source: European Annals of Otorhinolaryngology, Head and Neck DiseasesAuthor(s): H.J. Jung, G.H. Yu, J.H. ParkAbstractIntroductionHypereosinophilic syndrome is a rare disease with hypereosinophilia resulting in end-organ dysfunction. Patients present with organ-associated symptoms, and the targets frequently affected are heart, lung, skin, or the nervous system, and the middle ear involvement is rare.Case reportA 30-year-old female with left ear fullness…

Otorhinolaryngology

1d

Mark above section as read

www.hindawi.com?w=16&cs=679371232 Case Reports in Otolaryngology

A Rare Presentation of Inflammatory Myofibroblastic Tumor in the Nasolabial Fold
Inflammatory myofibroblastic tumor (IMT) is a benign lesion that occurs most frequently in the soft tissues and viscera. In the head and neck region, the tumor has been reported to occur in the orbit, tongue, nasopharynx, larynx, and paranasal sinuses and the central nervous system. Despite being a benign lesion, it exhibits infiltrative and destructive behaviours, making histopathological examination necessary to confirm the diagnosis. We report the case of a 38-year-old female presented with a…

Case Reports in Otolaryngology

1d

Mark above section as read

onlinelibrary.wiley.com?w=16&cs=2445351848 Clinical Otolaryngology

Comparing Gelfoam vs. fat as a sealing material in stapedotomy; A prospective double blind randomized clinical trial
Abstract Objectives One research aspect of stapes surgery is various materials that are used to seal the oval window. Several materials are used to seal the oval window, for example; adipose tissue, perichondrium, vein graft, gelatin sponge (Gelfoam), blood clot, and soft connective tissue. Up to now, there has been no randomized clinical trial that has evaluated the effects of different types of sealing material on hearing outcomes after stapedotomy. Hence, the present study aimed to find out…

Clinical Otolaryngology

3h

Our experience of shorter stay and lower cost for local versus general anaesthetic placement of tracheoesphageal fistulae in 27 patients
Abstract Secondary trache‐oesophageal puncture and fistula formation is often undertaken after laryngectomy to restore voice. The procedure was historically carried out under general anaesthesia (GA). This has been largely supplanted by local anaesthetic (LA) techniques as GA puts patients at a greater risk and the procedure is a more technically difficult undertaking. LA techniques have, however, never been validated against GA techniques in terms of length of stay, cost and complication rates….

Clinical Otolaryngology

1d

Recurrent Bell’s palsy
Abstract Objective Although recurrent facial palsy was first reported in 1871, the etiology, definitions, classifications, pathogenesis, treatment options, and prognosis have not been clearly determined. There have been no systematic reviews and meta‐analyses of recurrent Bell’s palsy. The purpose of this study was to evaluate the clinical manifestations of recurrent Bell’s palsy through a systematic review and meta‐analysis. Design The SCOPUS, PubMed, Cochrane Library, and EBSCO databases…

Clinical Otolaryngology

1d

Validation of french versions of the facial disability index (fdi) and the facial clinimetric evaluation (face) scale, specific quality of life scales for peripheral facial palsy patients
Abstract Objectives To translate and validate French versions of two health‐related quality of life questionnaires for patients with peripheral facial palsy: Facial Disability Index (FDI) and Facial Clinimetric Evaluation (FaCE) scale. Design Prospective cohort study. Setting University tertiary referral center. Participants A pilot test was performed on 10 subjects (5 patients with facial palsy of more than 1‐month duration and 5 normal subjects), then 67 adult patients with…

Clinical Otolaryngology

1d

Mark above section as read

www.sciencedirect.com?w=16&cs=1235559972 American Journal of Otolaryngology

Management of jugular bulb injury during drilling of the internal auditory canal (ICA) for vestibular schwannoma surgery
Publication date: Available online 24 January 2019Source: American Journal of OtolaryngologyAuthor(s): Sajjad Muhammad, Martin Lehecka, Saku T. Sinkkonen, Mika NiemeläAbstractThe retrosigmoid approach for vestibular schwannoma surgery has remained the standard approach by most neurosurgeons. Drilling the posterior wall of the internal auditory meatus (IAM) is an essential step in removing the intrameatal tumor. During IAM drilling, three anatomical structures can be encountered, including the posterior…

American Journal of Otolaryngology

4h

Impact of allergic rhinitis on quality of life after powered intracapsular tonsillectomy and adenoidectomy
Publication date: Available online 22 January 2019Source: American Journal of OtolaryngologyAuthor(s): Su Jin Kim, Ho Yun Lee, Jung Wook Kang, Oh. Eun Kwon, Kun Hee LeeAbstractBackgroundAllergic rhinitis (AR) has been reported to worsen quality of life (QoL) after adenotonsillectomy. Although powered intracapsular tonsillectomy and adenoidectomy (PITA) has been widely performed, it is not clear whether comorbid AR may worsen QoL in patients who undergo PITA.PurposeTo evaluate QoL after PITA in relation…

American Journal of Otolaryngology

1d

Mark above section as read

www.sciencedirect.com?w=16&cs=1235559972 Pediatric Otorhinolaryngology

A cross-sectional evaluation of outcomes of pediatric branchial cleft cyst excision
Publication date: Available online 23 January 2019Source: International Journal of Pediatric OtorhinolaryngologyAuthor(s): Jillian Mattioni, Sarah Azari, Travis Hoover, Daniel Weaver, Sri Kiran ChennupatiAbstractObjectiveTo examine complications following pediatric branchial cleft cyst excision by surgical specialty, demographics, and comorbid conditions.MethodsA retrospective review of the National Surgical Quality Improvement Program database was performed. Pediatric cases from January 1, 2015…

Pediatric Otorhinolaryngology

1d

Acute otitis media in infants younger than two months of age: Epidemiologic and microbiologic characteristics in the era of pneumococcal conjugate vaccines
Publication date: Available online 23 January 2019Source: International Journal of Pediatric OtorhinolaryngologyAuthor(s): Oren Ziv, Mordechai Kraus, Racheli Holcberg, Anat Bahat Dinur, Sofia Kordeluk, Dan Kaplan, Hadar Naidorf Rosenblatt, Shalom Ben-Shimol, David Greenberg, Eugene LeibovitzAbstractObjectivesTo evaluate the epidemiology, microbiology, Streptococcus pneumoniae serotypes distribution and serious bacterial infections (SBIs) occurrence in infants <2 months of age with tympanocentesis-documented…

Pediatric Otorhinolaryngology

1d

Metastatic Cellular Neurothekeoma in Childhood
Publication date: Available online 22 January 2019Source: International Journal of Pediatric OtorhinolaryngologyAuthor(s): Kaitlyn Zenner, John Dahl, Gail Deutsch, Erin Rudzinski, Randall Bly, Jonathan A. Perkins

Pediatric Otorhinolaryngology

1d

Endoscopic Arytenoid Abduction Lateropexy for the treatment of Neonatal Bilateral Vocal Cord Paralysis – long-term results
Publication date: Available online 22 January 2019Source: International Journal of Pediatric OtorhinolaryngologyAuthor(s): Balázs Sztanó, Ádám Bach, Vera Matievics, Eszter Erdélyi, Ilona Szegesdi, Christopher T. Wootten, László RovóABSTRACTOBJECTIVESBilateral vocal cord paralysis often causes severe dyspnea requiring an early airway intervention in neonates. Endoscopic arytenoid abduction lateropexy (EAAL) with suture is a quick, reversible, minimally-invasive vocal cord lateralizing technique to…

Pediatric Otorhinolaryngology

1d

Prospective analysis of mid-facial fractures in a single-center pediatric-adolescent cohort
Publication date: Available online 22 January 2019Source: International Journal of Pediatric OtorhinolaryngologyAuthor(s): Waldemar Reich, Oliver Aust, Alexander EckertAbstractBackgroundThe complex architecture of the midface renders diagnosing and treating fractures challenging, especially for young patients who present the additional risk of suffering growth and development deficiencies, which is to be avoided at all costs.ObjectivesThis study sought to characterize pediatric mid-facial fractures…

Pediatric Otorhinolaryngology

1d

Mark above section as read

www.sciencedirect.com?w=16&cs=1235559972 Otolaryngology-Head and Neck Surgery

Open anterior skull base surgery in the pediatric population: anatomy, approaches, and considerations
Publication date: Available online 24 January 2019Source: Operative Techniques in Otolaryngology-Head and Neck SurgeryAuthor(s): Tristan Tham, Peter CostantinoThe objectives of this paper are to synthesize the existing literature on open approaches to the anterior skull base in children. First, we review the developmental anatomy of the anterior skull base. Next, we describe the most commonly used open approaches to the anterior skull base and other adjunctive procedures. Lastly, we review the reconstructive…

Otolaryngology-Head and Neck Surgery

5h

Surgical management of nasal dermoid lesions
Publication date: Available online 23 January 2019Source: Operative Techniques in Otolaryngology-Head and Neck SurgeryAuthor(s): Craig Miller, Scott Manning, Randall BlyNasal dermoids are the most common congenital midline nasal lesions. They often present as a midline pit or nasal mass and arise from incomplete or failed regression of the dural diverticulum during embryogenesis. Management requires complete resection of the tract and an appropriate surgical approach is based on location, extent,…

Otolaryngology-Head and Neck Surgery

1d

Introduction
Publication date: Available online 23 January 2019Source: Operative Techniques in Otolaryngology-Head and Neck SurgeryAuthor(s): Meghan N. Wilson

Otolaryngology-Head and Neck Surgery

1d

Otolaryngology

European archives of oto-rhino-laryngology

The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino

Decreased Treg-derived miR-181a and miR-155 correlated with reduced number and function of Treg cells in allergic rhinitis children.
Decreased Treg-derived miR-181a and miR-155 correlated with reduced number and function of Treg cells in allergic rhinitis children. Eur Arch Otorhinolaryngol. 2019 Jan 23;: Authors: Liu W, Ouyang H, Zeng Q, Luo R, Lu G Abstract BACKGROUND: Regulatory cells (Tregs) have been proved to be deeply involved in allergic airway inflammation. This study aims to evaluate the expression of miRNA in children with AR and their association with Tregs as well as…

archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino

2h

Salvage surgery for advanced stage head and neck squamous cell carcinoma following radiotherapy or chemoradiation.
Salvage surgery for advanced stage head and neck squamous cell carcinoma following radiotherapy or chemoradiation. Eur Arch Otorhinolaryngol. 2019 Jan 23;: Authors: Elbers JBW, Veldhuis LI, Bhairosing PA, Smeele LE, Jóźwiak K, van den Brekel MWM, Verheij M, Al-Mamgani A, Zuur CL Abstract PURPOSE: Salvage surgery for recurrent advanced stage head and neck squamous cell carcinoma (HNSCC) is known to result in poor prognosis. As there are only small and…

archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino

2h

Acute invasive fungal rhinosinusitis: our 2 year experience and outcome analysis.
Related ArticlesAcute invasive fungal rhinosinusitis: our 2 year experience and outcome analysis. Eur Arch Otorhinolaryngol. 2019 Jan 22;: Authors: Shanbag R, Rajan NR, Kumar A Abstract PURPOSE: The incidence of Acute invasive fungal rhinosinusitis (AIFRS) is on the rise considering the multitude of comorbidities present in a single patient.The delay in suspecting the fungal etiology, presentation of the patient for an Otorhinolaryngology consult and…

archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino

2h

Is intensity-modulated radiotherapy superior to conventional techniques to prevent late ear complications of nasopharyngeal cancer?
Related ArticlesIs intensity-modulated radiotherapy superior to conventional techniques to prevent late ear complications of nasopharyngeal cancer? Eur Arch Otorhinolaryngol. 2019 Jan 22;: Authors: Ant A, Yazici Ö, Atabey P, Aslan FF, Duran A, Ozlugedik S, Kemaloglu YK Abstract PURPOSE: This study analyzed the late ear complications of radiotherapy for nasopharyngeal cancer (NPC) and compared the conventional and intensity-modulated radiotherapy (2D-RT…

archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino

2h

Outcomes of salvage surgery for the oropharynx and larynx: a contemporary experience in a UK Cancer Centre.
Related ArticlesOutcomes of salvage surgery for the oropharynx and larynx: a contemporary experience in a UK Cancer Centre. Eur Arch Otorhinolaryngol. 2019 Jan 21;: Authors: Hay A, Simo R, Hall G, Tharavai S, Oakley R, Fry A, Cascarini L, Lei M, Guerro-Urbano T, Jeannon JP Abstract INTRODUCTION: The purpose of this study was to review our recent experience of salvage surgery, comparing larynx and oropharynx recurrence patterns. METHODS: A single…

archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino

1d

Correlation between the duration of locoregional control and survival in T1-T2 oropharyngeal cancer patients.
Related ArticlesCorrelation between the duration of locoregional control and survival in T1-T2 oropharyngeal cancer patients. Eur Arch Otorhinolaryngol. 2019 Jan 21;: Authors: Caula A, Boukhris M, Guerlain J, Tao Y, Breuskin I, Mirghani H, Temam S, Gorphe P Abstract PURPOSE: To investigate the correlation between the time to locoregional recurrence and survival in T1-T2 oropharyngeal squamous-cell carcinoma (OPSCC) patients. METHODS: A retrospective,…

archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino

1d

Effects of treatment on anxiety levels among patients with benign paroxysmal positional vertigo.
Related ArticlesEffects of treatment on anxiety levels among patients with benign paroxysmal positional vertigo. Eur Arch Otorhinolaryngol. 2019 Jan 21;: Authors: Gunes A, Yuzbasioglu Y Abstract PURPOSE: The association of vertigo with anxiety disorders is well known. Herein, we aimed to determine the relationship between pre-treatment and post-treatment anxiety levels, assessed with Beck anxiety inventory, with educational status among patients diagnosed…

archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino

1d

European archives of oto-rhino-laryngology

The Laryngoscope


onlinelibrary.wiley.com?w=16&cs=2445351848 The Laryngoscope

Establishment and verification of a mouse model of nasal wound healing
Objectives Poor wound healing as reflected by the development of synechia and osteitis after endoscopic sinus surgery may trigger disease recurrence. Animal models provide insights into the pathogenesis of poor wound healing and may aid in the development of new therapeutics. Here, we established a mouse model of nasal wound healing and confirmed its utility. Study Design Animal study. Methods Unilateral intranasal wounds were induced using a small interdental brush in 6‐week‐old C57BL/6…

The Laryngoscope

4h

Taste disorders are partly genetically determined: Role of the TAS2R38 gene, a pilot study
Objectives/Hypothesis Taste sensitivity varies greatly among individuals influencing eating behavior and health, consequently the disorders of this sense can affect the quality of life. The ability to perceive the bitter of thiourea compounds, such as phenylthiocarbamide (PTC), has been largely reported as a marker of the general taste sensitivity, food preferences, and health. PTC sensitivity is mediated by the TAS2R38 receptor and its genetic common variants. We study the role of the TAS2R38 receptor…

The Laryngoscope

4h

Somatosensory evoked potential: Preventing brachial plexus injury in transaxillary robotic surgery
Objectives/Hypothesis The potential for brachial plexopathy due to arm positioning is a major concern regarding the robotic transaxillary approach. Intraoperative nerve monitoring via somatosensory evoked potential (SSEP) has been suggested to prevent such injury. In this study, we examined the use of SSEP in detecting imminent brachial plexus traction during robotic transaxillary thyroid and parathyroid surgery. Study Design Retrospective case series. Methods A analysis was performed…

The Laryngoscope

1d

Comparative Assessment of Drug‐Induced Sleep Endoscopy Scoring Systems in Pediatric Sleep Apnea
Objectives/Hypothesis A wide variety of drug‐induced sleep endoscopy (DISE) scoring systems has been used to evaluate sites of upper airway obstruction in children and adults; however, a universally accepted DISE scoring system dedicated to children has not been developed. We evaluated the utility of DISE scoring systems in the assessment of obstructive sleep apnea (OSA) using a single cohort of pediatric patients. Study Design Retrospective chart review. Methods The medical records…

The Laryngoscope

1d

Pediatric dysphagia: Is interarytenoid mucosal height significant?
Objectives The clinical significance of the interarytenoid mucosal height (IAMH) in pediatric dysphagia, ranging from normal anatomy to a laryngeal cleft, is unknown. This study seeks to evaluate a cohort of patients who underwent evaluation of their IAMH during microdirect laryngoscopy (MDL) for associations between IAMH and dysphagia as diagnosed on preoperative videofluoroscopic swallow study (VFSS). Methods A retrospective case series of 1,351 patients who underwent MDL between 2011 and…

The Laryngoscope

1d

Validation of the Chinese Velopharyngeal Insufficiency Effects on Life Outcomes Instrument
Objectives/Hypothesis To translate the Velopharyngeal Insufficiency Effects on Life Outcomes (VELO) instrument into Chinese and test its psychometric properties. Study Design Quality of life instrument translation and validation. Methods The original English version of the VELO instrument was translated into Mandarin, back‐translated, and adapted among the Chinese population, based on the standardized guidelines for the cross‐culture adaption process. Velopharyngeal insufficiency (VPI)…

The Laryngoscope

1d

The Laryngoscope

Ophthalmology

EDITORIAL
Driving blind – Should tests of visual function be mandatory for driving license? Highly accessed article p. 193
Santosh G Honavar
DOI:10.4103/ijo.IJO_150_19
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
ONE MINUTE OPHTHALMOLOGY Top
zoom.png Just another chalazion? p. 195
Jonathan McLaughlin, Sara E Lally, Carol L Shields
DOI:10.4103/ijo.IJO_18_19
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
REVIEW ARTICLE Top
zoom.png Visual function assessment, ocular examination, and intervention in children with developmental delay: A systematic approach. Part 1 p. 196
Meenakshi Swaminathan, Deiva Jayaraman, Namita Jacob
DOI:10.4103/ijo.IJO_524_18 Children with special needs form a unique subset with regards to visual function and examination techniques needed to assess them. With more awareness among the general public, neurologists, and pediatricians, these children are referred for assessment to the ophthalmologist or optometrist and sometimes even to the rehabilitation professional at an early age. This clinical practice guideline and review gives a systematic approach for examining the visual functions of a child with special needs. It outlines the procedures to be followed with equipment needed in clinical practice. Functional vision assessment guidelines are also included. This is the first part in a two-part series, with the first part presenting clinical examination guidelines and the second presenting intervention and vision enhancement techniques.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
ORIGINAL ARTICLES Top
Causes of visual impairment in applications for blindness certificates in a tertiary center of Bihar and its role in health planning p. 204
Anita Ambastha, Rakhi Kusumesh, Shalini Sinha, Bibhuti P Sinha, Gyan Bhasker
DOI:10.4103/ijo.IJO_837_18 Purpose: To analyze applications for blindness certificates to find causes of visual impairment (VI), handicap, and blindness in a tertiary hospital of Bihar. Methods: Applications for blindness certificates were analyzed over a two-year period. The main cause of blindness, visual handicap, and VI in these applications was ascertained by age group and etiology. VI disability percentages and definitions proposed by Governmen of India (category 0–4; 20–100%) were used to categorize and give percentage to all applicants. Results were compared with data from studies on blindness certificates and population based studies. Results: In total, 203 applicants were reviewed. Mean age was 23.5 ± 7.9 years. Overall, most common cause of visual handicap (40–100% impairment) and blindness (75–100% impairment) was macular pathology (P <.05), while most common cause of overall VI (20–100% impairment) was amblyopia. In age group 0–15 years, most common causes of blindness/visual handicap were congenital globe and hereditary retinal or optic nerve disorders (P = 0.016). In age group 16–30 years, macular pathology was the most common cause of visual handicap [P = 0.007], while amblyopia was the most common cause of VI [P = 0.00]. Between 31 and 45 years of age group, corneal scar in one eye was the most common cause of VI, while macular scar in both eyes was the most common cause of visual handicap. Glaucoma and diabetic retinopathy were the most common causes of blindness/visual handicap between 46 and 65 years and above 65 years of age, respectively. Data about causes of VI such as amblyopia, complicated cataract surgery, and one eyed blindness could not be ascertained by analyzing blindness certificate alone. Conclusion: Data from applications for blindness certificates provide valuable information regarding different causes of VI that might otherwise not be eligible for blindness certification and provide an insight into the overall trends in disease profile and service delivery.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Iris and knot configuration after Single Pass Four Throw (SFT) pupilloplasty as imaged by the spectral-domain optical coherence tomography p. 209
Dhivya Ashok Kumar, Amar Agarwal, Radhika Chandrasekar, Nagaraj Jaganathasamy
DOI:10.4103/ijo.IJO_885_18 Purpose: To analyze the morphological changes in the iris-knot complex configuration using spectral-domain optical coherence tomography (SD-OCT) following the single pass four throw (SFT) pupilloplasty. Methods: In this retrospective case series, eyes with SFT pupilloplasty were examined by SD-OCT (Optovue). Iris morphology compared to the normal iris, presence of specific patterns (single hump, double humps, peaks and valleys, tethering), prolene suture, knot complex (length and orientation), and intraocular lens (IOL) vault were evaluated. Results: Overall, 41 knots of 26 patients with a mean time duration of 3.1 ± 2 months from surgery were analyzed. Iris configurations seen were single hump (n = 28, 63.8%), double humps (n = 7, 17%), loop (n = 2, 4.8%), flat (n = 3, 7.3%), and mulberry (n = 1, 2.4%). The mean length and the height of the knot complex was 784.1 ± 433.7 μm and 317.7 ± 110.4 μm, respectively. Knot positions were at 3 clock hours in 9 eyes (21.9%), 9 in 8 eyes (19.5%), and others in 24 eyes (58.5%). Cut end of the prolene suture was detectable in 26 eyes (63.4%) as hyper-reflective line, and the mean cut length was 465.8 ± 321.1 μm. The suture was predominantly vertically oriented (80.6%) to the iris with a mean distance of 3.6 ± 0.3 mm (2.6–4 mm) away from corneal endothelium. The mean distance from the knot complex and the IOL was 289.2 ± 146 μm and the mean anterior chamber depth was 4.1 ± 0.1 mm. Conclusion: A significant change in iris configuration was noted after SFT pupilloplasty, and vertically oriented retained prolene suture was predominant with good endothelial vault.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
Perceived difficulties and complications in learners of phacoemulsification: A principal component analysis model p. 213
Sagnik Sen, Mukesh Patil, Rohit Saxena, Atul Kumar, Sreelakshmi P Amar, Deepsekhar Das, Anand Singh Brar, Pragya Saini
DOI:10.4103/ijo.IJO_1133_18 Purpose: To evaluate the difficulty perceived of each step of phacoemulsification and analyze the factors affecting them. Methods:Overall, 12 trainee residents were allotted 10 cases of phacoemulsification of eyes with senile cataract, under a single observer, and the steps of each surgery were rated from very easy to very difficult with a questionnaire. The completion rates of steps and complications of each surgery were noted. Principal component analysis of the responses to the difficulty level questionnaire was conducted to obtain factors resulting in the perceived difficulty. Results: The lowest difficulty scores were for initial step of incision creation (1.63 ± 0.84), followed by intraocular lens insertion (2.51 ± 0.8). The most difficult step was divide/chop of the nucleus (3.74 ± 0.97) followed by phacoemulsification (3.32 ± 0.82). Highest completion rates were seen for the initial steps of the surgery and the lowest for divide/chop. We identified two major patterns of difficulty among the trainees – one for steps involving high amount of binocularity and the other, for steps involving high precision of hand control. The rate of complication of our study was within acceptable range. Conclusion: Although trainees have practiced phacoemulsification steps on simulation, real-life situation may bring in unprecedented level of difficulty and challenges, which may be documented and used for targeted improvement of surgical skills. Stereopsis and hand control training should form a major part of training modules of cataract surgery both on simulation and real-life scenarios.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Retrospective study on outcomes of terminal chop technique of nuclear fragmentation in phacoemulsification and combined surgery: An observational study p. 217
Arvind K Morya, Sahil Bhandari, Anushree Naidu
DOI:10.4103/ijo.IJO_711_18 Purpose: Terminal chop, a new technique of nuclear segmentation, has been recently described in literature. The technique is considered to be a safe and effective option. Methods: We did a retrospective study to evaluate the outcome of terminal chop. Patients operated for terminal chop (phacoemulsification with or without trabeculectomy) from October 2016 to July 2018 were included in the study. Results: In all, 933 patients were included in the study. The grade of nuclear sclerosis ranged from 2 to 5. All the patients had a significant visual improvement at 1 month postop. Around 3.4% had pseudoexfoliation and 8.89% of the eyes underwent combined surgery. Cumulative dissipated energy showed a proportionate relation with the grade of nucleus. Intraoperative complication rate was 0.08%. Postoperative complication rate was 3.50%. Conclusion: Terminal chop proved to be a safe, reproducible, and effective technique of nuclear segmentation in different grades of cataract.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Frequency and surgical difficulties associated with pseudoexfoliation syndrome among Indian rural population scheduled for cataract surgery: Hospital-based data p. 221
Rajesh S Joshi, Sonali V Singanwad
DOI:10.4103/ijo.IJO_931_18 Purpose: To study the frequency and intraoperative difficulties associated with pseudoexfoliation (PXF) syndrome at a tertiary eye care center in a rural central India. Methods: This study included patients scheduled for cataract surgery who were diagnosed with PXF syndrome. All patients underwent a complete ophthalmologic evaluation, including slit-lamp examination, tonometry, gonioscopy, and ophthalmoscopy before the surgery. Cataract surgeries were performed by a single surgeon who reported the intraoperative difficulties. Results: In total, 1022 phakic eyes of 1823 patients were evaluated, 226 of whom (22.1%) were diagnosed with PXF syndrome. Most eyes (n = 81, 35.8%) with PXF syndrome were ≥81 years old. Eighty-six eyes (38.1%) had bilateral involvement, whereas 70 (30.9%) had right or left eye involvement. Further, PXF material was distributed on the iris, pupil, and lens in 70 eyes (30.9%) and on the pupillary margin in 36 eyes (15.9%). The mean pupillary dilation was 5.1 (±1.4) mm in patients with PXF syndrome compared with 7.2 (±1.6) mm in those without it (P = 0.03). Grade VI cataract was observed in 93 eyes (41.2%) and hypermature cataract was the most commonly observed cataract stage. Twenty-one eyes (9.3%) had increased intraocular pressure. Intraoperative difficulties were encountered in 62 eyes (27.4%) with poor pupillary dilation being the most common problem (32 eyes, 14.2%), followed by zonular dehiscence (18 eyes, 8%). Conclusion: This hospital-based study showed that PXF syndrome is common in Indian rural population and that the intraoperative complication rate in these patients is high.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Quantification of RAPD by an automated pupillometer in asymmetric glaucoma and its correlation with manual pupillary assessment p. 227
Manju R Pillai, Sapna Sinha, Pradeep Aggarwal, Ravilla D Ravindran, Claudio M Privitera
DOI:10.4103/ijo.IJO_648_18 Purpose: The relative afferent pupillary defect (RAPD) is an important sign of asymmetrical retinal ganglion cell damage. The purpose of this study was to quantify RAPD by a pupillometer (RAPiDo, Neuroptics) and assess its correlation with asymmetric glaucoma and manual pupillary assessment. Methods: A total of 173 subjects were enrolled in the study and categorized into glaucoma, n = 130, and control, n = 43. Subjects were all recruited in the Glaucoma Clinic of the Aravind Eye Hospital in Madurai during their follow-up. They were 18 years and older, with best corrected visual acuity of 6/36 or better. Exclusion criteria included all retinal pathologies, optic atrophies, ocular injuries, severe uveitis, cloudy corneas, dense cataracts, or use of mydriatics or miotic drugs. RAPD was assessed in all subjects using an automated pupillometer and the results were compared with the swinging flash light test conducted on the same subjects by an experienced ophthalmologist. We looked at the correlation between RAPD and the intereye difference in cup-to-disc ratio (CDR), mean deviation (MD) of visual field testing, and retinal nerve fiber layer (RNFL) thickness. Sensitivity and specificity were assessed by area under the receiver operator characteristic (AUROC) analysis. Results: Glaucoma patients had significant RAPD (0.55 ± 0.05 log units) when compared with the controls (0.25 ± 0.05 log units), P < 0.001. Significant intereye differences in CDR, MD, and RNFL between glaucoma and control (P < 0.001) were seen. There was a good correlation between the magnitude and sign of RAPD and these intereye differences in CDR (r = 0.52, P < 0.001), MD (r = 0.44, P < 0.001) and RNFL thickness (r = 0.59, P < 0.001). When compared with the experienced ophthalmologist, AUROC was 0.94, with 89% sensitivity and 91.7% specificity. Conclusion: The good correlation between the magnitude of RAPD, as measured by the automated pupillometer, and intereye differences in MD, CDR, and RNFL thickness in glaucomatous, and the good sensitivity and specificity when compared with the experienced ophthalmologist, suggest that pupillometry may be useful as a screening tool to assess asymmetric glaucoma.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Intermediate-term outcome of Aurolab aqueous drainage implant p. 233
Reji Philip, Premanand Chandran, Nabeed Aboobacker, Mrunali Dhavalikar, Ganesh V Raman
DOI:10.4103/ijo.IJO_675_18 Purpose: To report the intermediate-term safety and efficacy of Aurolab aqueous drainage implant (AADI) in patients with glaucoma. Methods: Retrospective review of patients who underwent AADI between January 2013 and December 2016. Patients aged >16 years and with a minimum follow-up of 6 months were included. Success was defined as complete when the intraocular pressure was ≥6 and ≤21 mmHg without antiglaucoma medication and as qualified if those requiring additional antiglaucoma medications were included. Results: The study included 55 patients (55 eyes) with a mean age ± standard deviation (SD) of 47.3 ± 18.1 years with a mean follow-up of 16.7 ± 11.4 months. Mean intraocular pressure reduced from 30.8 ± 11.1 mmHg to 13.1 ± 4.7, 14.1 ± 4.8, 15.7 ± 2.5 (P < 0.001) mmHg at 6 months, 1 year, and 2 years, respectively. The mean number of antiglaucoma medications reduced from 3.4 ± 1 to 0.8 ± 1.2, 0.7 ± 1.1, 0.8 ± 1 (P < 0.001) at 6 months, 1 year, and 2 years, respectively. The cumulative probability of complete and qualified success was 62% and 100% at 6 months, 54% and 92% at 1 year, and 43% and 88% at 2 years, respectively. Four patients failed during the follow-up period. Postoperative complication occurred in 28 eyes (51%), of which 17 eyes (31%) required intervention. Conclusion: AADI is a safe and effective treatment for the control of intraocular pressure in patients with glaucoma.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
COMMENTARY Top
Commentary on: Glaucoma drainage devices: Boon or bane p. 238
Sushmita Kaushik
DOI:10.4103/ijo.IJO_1234_18
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
ORIGINAL ARTICLES Top
zoom.png Renewal of driving license in India and glaucoma: A study of prevalent practice and its lacunae p. 240
Gowri J Murthy, Ajinkya V Deshmukh, Ayyappa R Mallidi, Praveen R Murthy, Jyoti S Kattige, Vinay R Murthy
DOI:10.4103/ijo.IJO_776_18 Purpose: Glaucoma affects different aspects of vision including visual field. This prospective observational study aims to collect details of driving license (DL) renewal procedure (in an urban metro in India) among patients with diagnosed glaucoma and the method of reporting of vision-related requirements during renewal. Methods: One-hundred patients with diagnosed glaucoma above 40 years, having valid DL (with at least one renewal cycle), were included. Patients with other ocular comorbidities were excluded. Driving Habits Questionnaire and a questionnaire about license renewal were administered. Driving eligibility was compared to international guidelines. Results: Study population included patients with 69% early, 29% moderate, and 2% advanced glaucoma. Sixteen percent of patients had stopped driving. Legal license renewal procedure was bypassed by 45%. Form-1 was not submitted by 43% and 49% did not submit Form-1A at the time of renewal. Only 7.01% mentioned about glaucoma in the self-declaration form. None were asked about their visual field during renewal. Among 61 patients who submitted a medical certificate, the undersigning doctor was an ophthalmologist in only six patients. Thirty percent patients with valid Indian DL would not have satisfied International College of Ophthalmologists guidelines. Driving difficulties were experienced by 44%, more so in advanced glaucoma (F (1, 82) = 22.12, P < 0.001). Conclusion: Vision-related testing at the time of renewal of DL is inadequate in India. Chronic eye diseases such as glaucoma are commonly not self-declared or detected at pre-renewal testing. Clear-cut guidelines about visual requirements and implementation are required to prevent road traffic events because of vision-related errors.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Clinical profile of uveitis patients developing central serous chorioretinopathy: An experience at a tertiary eye care center in India p. 247
Parthopratim Dutta Majumder, Nitin Menia, Sridharan Sudharshan, Chetan Rao, Sudha K Ganesh, Jyotirmay Biswas
DOI:10.4103/ijo.IJO_831_18 Purpose: To evaluate clinical profile of patients with uveitis who developed central serous chorioretinopathy (CSC). Methods:Retrospective case series of consecutive patients of uveitis with CSC managed at a tertiary eye care center in India between 1994 and 2014. The data about clinical features, investigations, treatment, and outcomes were obtained from their medical records. Results: A total of 31 eyes of 26 patients with uveitis with a diagnosis of CSC between June 1994 and May 2014 were included in the study. The mean age of presentation was 42.8 ± 9.2 years, and 88.4% of the patients were male. CSC was bilateral in 19.2% of the patients, and in 38.4% patients uveitis was because of infectious etiology. CSC developed in 23 (88.5%) patients when they were on oral corticosteroid. The most common cause of uveitis in our study was choroiditis (48.4%), followed by retinal vasculitis (12.9%). The mean time for resolution of CSC was relatively less in patients with uveitis because of infectious etiology. In 10% eyes vision remained the same and deterioration of vision was noted in 19% eyes. Best corrected visual acuity of the patients at the time of presentation with CSC was 0.56 ± 0.34 and after the resolution of CSC was 0.48 ± 0.5 (P < 0.0005). Conclusion: Patients with choroidal inflammations are more prone to develop CSC compared with other subtypes of uveitis. Management of CSC in uveitis can be challenging.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Choroidal thickness in normal Indian eyes using swept-source optical coherence tomography Highly accessed article p. 252
Amber A Bhayana, Vinod Kumar, Akshay Tayade, Mahesh Chandra, Parijat Chandra, Atul Kumar
DOI:10.4103/ijo.IJO_668_18 Purpose: The purpose of this study is to provide normative database for subfoveal choroidal thickness in Indian eyes using swept-source optical coherence tomography. Methods: This is a cross-sectional study based at a tertiary eye care center in Northern India. Two hundred and thirty eight eyes of 119 healthy subjects were examined in terms of axial length, spherical equivalent, and choroidal thickness. Inclusion criteria included age 19–60 years, no retinal or choroidal disorder, and patients with clear media and good fixation. Patients with high hypermetropia (>4 D) or myopia (>6 D) or any systemic disease likely to affect choroidal thickness were excluded. Twelve radial line scans were obtained centered on the fovea that were used to calculate choroidal and retinal thickness in 9 early treatment diabetic retinopathy study (ETDRS) zones. Results: The mean age of all the subjects was 28.70 ± 11.28 years; mean axial length was 23.63 ± 1.96 mm, and mean spherical equivalent was − 0.92 ± 3.08 D. The mean subfoveal choroidal thickness was 299.10 ± 131.2 μ and mean foveal thickness was 239.92 ± 48.16 μ. A negative correlation was found between subfoveal choroidal thickness and age (r = −0.0961, P = 0.1392) and axial length (r = −0.3166, P < 0.001). A statistically significant positive correlation was found between subfoveal choroidal thickness and refractive error (r = 0.2393, P = 0.0002). Conclusion: This study provides normative database for subfoveal choroidal thickness and foveal thickness using swept-source optical coherence tomography. The choroidal thickness measured with swept-source platform is slightly higher than that reported with spectral domain platforms.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
COMMENTARY Top
Commentary: Choroidal thickness in the era of swept-source optical coherence tomography p. 256
Aniruddha Agarwal
DOI:10.4103/ijo.IJO_1893_18
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
ORIGINAL ARTICLE Top
zoom.png Outcome of delayed adjustable strabismus surgery in children using a bow-tie optional adjustable technique p. 258
R Muralidhar, Lal Churawan, M Sekar, AP Chidambaram, P Mugdha, D Ramamurthy
DOI:10.4103/ijo.IJO_398_18 Purpose: The aim of this article is to study the feasibility of a delayed adjustable technique of strabismus surgery in children using an optional adjustable suture technique. Methods: The retrospective study included patients <12 years of age. Recessions were done using an optional adjustable bow-tie technique and resections were done by the conventional technique. Patients were evaluated on the third postoperative day and adjustments done when needed. Statistical analysis was done using Microsoft Excel 2010®. Results: The study included 11 patients with exotropia and 16 patients with esotropia. The mean age of the patients was 5.2 years (range 1–11 years). The mean preoperative distance deviation was 46.7 ± 10.4 prism diopters (PD) for exotropic patients and 47.1 ± 16.9 PD for esotropic patients. The mean preoperative near deviation was 46.6 ± 11 PD for exotropic patients and 52.4 ± 17.1 PD for esotropia. Two patients with exotropia (18.2%) and four patients with esotropia (25%) were adjusted under intravenous ketamine in the operating room under anesthetist supervision. No difficulty was encountered in advancing/recessing the muscles. The success rate at 1 month was 100% for exotropia and 87.5% for esotropia. The success rate at the final follow-up was 81.8% for patients with exotropia and 68.7% for patients with esotropia. Conclusions: This delayed optional adjustable strabismus surgery technique provides good short-term results and lower adjustment rates.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
COMMENTARY Top
Commentary: Adjustable strabismus surgery p. 263
Rohit Saxena, Rebika Dhiman
DOI:10.4103/ijo.IJO_1000_18
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
SURGICAL TECHNIQUE Top
zoom.png Modified Faden operation –A new surgical technique p. 264
Manjula Jayakumar, Suganya Vel, Amar Agarwal
DOI:10.4103/ijo.IJO_952_18 Faden operation was first described in 1912. It weakens the muscle in its field of action without much slackening and alteration in the primary position. When combined with recession the weakening effect is more. It is a useful surgery in esotropia with high accommodative convergence, nystagmus blockage syndrome, dissociated vertical deviation, Duane’s retraction syndrome with up or downshoots, and in sixth nerve paresis, where it is performed on the contralateral normal yoke muscle to increase the field of binocular vision. The conventional procedure is cumbersome due to small working space, entanglement of sutures, and posterior location of Faden site which is not easily accessible. We have modified the Faden operation by using a single 5-0 double-armed polyester suture, which is much easier and simpler to perform, and have done it in a series of small angle esotropias combined with recession. This paper demonstrates the surgical technique so that this surgery can be performed with ease by more surgeons.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
PHOTO ESSAY Top
zoom.png Ocular argyrosis: A case with silver deposits in cornea and lens p. 267
Lakshey Dudeja, Ishani Dudeja, Anuja Janakiraman, Manohar Babu
DOI:10.4103/ijo.IJO_730_18
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Anterior chamber migration of intravitreal dexamethasone implant in glued intraocular lens p. 268
Dhivya Ashok Kumar, Atul Dhawan, Soumya Narayanan, Amar Agarwal
DOI:10.4103/ijo.IJO_841_18
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Hyperpigmented torpedo maculopathy p. 270
PC Ranjith, Anantharaman Giridhar
DOI:10.4103/ijo.IJO_886_18
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Pigmented paravenous retinochoroidal atrophy Highly accessed article p. 271
Saurabh Deshmukh, Dipankar Das, Hemalata Deka, Harsha Bhattacharjee, Awaneesh Upadhyay, Krati Gupta
DOI:10.4103/ijo.IJO_1202_18
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png A rare case having hemi-retinal artery occlusion in one eye and hemi-retinal vein occlusion in the other: Diverse manifestations of retinal vascular occlusion p. 273
Pulak Agarwal, Vinod Agarwal, Shorya Azad
DOI:10.4103/ijo.IJO_987_18
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
OPHTHALMIC IMAGES Top
zoom.png Bilateral vitritis as an initial presentation of primary central nervous system lymphoma p. 275
Nitin K Menia, Ranjan Behera, Reema Bansal, Nalini Gupta, Astha Takkar, Vivek Lal
DOI:10.4103/ijo.IJO_773_18
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png A complication of ischemic branch retinal vein occlusion p. 276
PC Ranjith, Anantharaman Giridhar
DOI:10.4103/ijo.IJO_882_18
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Congenital tortuous retinal vessels p. 277
Mohit Dogra, Mangat R Dogra
DOI:10.4103/ijo.IJO_1281_18
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Autofluorescence of optic disc drusens p. 278
Nitin K Menia, Swati Kiran, Reema Bansal
DOI:10.4103/ijo.IJO_888_18
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Endoscopic view of mascara laden lacrimal sac with canalicular involvement p. 279
Nishi Gupta, Smriti Bansal, Arpan Gandhi
DOI:10.4103/ijo.IJO_1348_18
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
CASE REPORTS Top
zoom.png Consecutive cyclic esotropia – A case report p. 280
Niranjan K Pehere, Usha B Kommineni, Ramesh Kekunnaya
DOI:10.4103/ijo.IJO_1018_18 Cyclic esotropia, a rare condition of obscure etiology characterized by regularly alternating periods of esotropia and orthophoria. We present a case of a 7-year-old boy who underwent surgical correction for intermittent exotropia elsewhere and developed esotropia with cyclic pattern post-operatively. Initially the cycle was of half-day orthophoria and half-day esotropia, which later became one full day of esotropia and one day of orthophoria. During re-surgery, right lateral rectus was found to have a stretched scar which was resected and then advanced and medial rectus was recessed. Post-surgery the child was orthophoric without cyclic pattern.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Human ocular thelaziasis caused by gravid Thelazia callipaeda – A unique and rare case report Highly accessed article p. 282
Meenakshi Sharma, Dipankar Das, Harsha Bhattacharjee, Saidul Islam, Nilutparna Deori, Gayatri Bharali, Sumegha Tomar, Priyank Bhola, Apurba Deka
DOI:10.4103/ijo.IJO_1110_18 An 80-year-old male reported to the clinic with complaints of diminished vision, foreign body sensation, and occasionally some black object moving in front of the right eye. Detailed ocular examination revealed three slender creamy white live worms in the conjunctival sac of the right eye. Total three worms were retrieved and sent to the pathology department for detailed examination. The worm was identified as gravid Thelazia callipaeda. As per the search results in PubMed and Cochrane search engine, this is the first report of human case of gravid Thelazia infestation with simultaneous existence of embryonated or ensheathed eggs and primary-stage larvae in the same worm.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Uncontrolled neovascular glaucoma – an alarming manifestation of chronic myeloid leukemia on imatinib therapy – a case report and review of literature p. 285
Prakhyat Roop, Dewang Angmo, Neha Kamble, Ankit S Tomar
DOI:10.4103/ijo.IJO_1288_18 A 45-year-old diabetic male, with diabetic retinopathy and medically uncontrolled neovascular glaucoma (NVG) underwent intracameral bevacizumab followed by trabeculectomy, with controlled intraocular pressures (IOP) post-operatively, OD: 12 mmHg; OS: 14 mmHg. Patient was referred to hematology, where he was diagnosed as chronic myeloid leukemia (CML) and started on imatinib mesylate. Thereafter, he presented with recurrence of neovascularization and vascularization of the bleb along with OS vitreous hemorrhage at 6 weeks follow-up. While he was planned for OS vitreo-retinal surgery, he presented with OD spontaneous hyphema with raised IOP (OD: 38 mmHg, OS: 16 mmHg). He had maintained a tight glycemic control. Following imatinib therapy, there was a rapid progression and recurrence of neovascularization, eventually leading to failure of trabeculectomy OD and bilateral severe loss of vision. Imatinib may be implicated in the worsening of NVG in CML patients, especially with co-existing diabetes and thus, such patients should receive regular thorough ophthalmic evaluation as long as imatinib continues.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Suprachoroidal hemorrhage after removal of releasable suture with globe massage post-trabeculectomy p. 287
Jyoti Shakrawal, Shreyas Temkar, Ramanjit Sihota, Pradeep Venkatesh
DOI:10.4103/ijo.IJO_452_18 A 19-year-old female, having aniridia with secondary glaucoma, presented with uncontrolled intraocular pressure (IOP) in the right eye (RE) on maximal topical and systemic medications. On examination, RE had a subluxated cataractous lens with advanced cupping. She underwent trabeculectomy with mitomycin C. On postoperative day 1, as the IOP was 32 mmHg, one releasable suture was removed followed by gentle bleb massage. On postoperative day 2, suprachoroidal hemorrhage was noted, for which the patient underwent two drainage procedures. Hemorrhagic choroidals resolved completely 4 weeks after drainage.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Macular toxicity after short-term hydroxychloroquine therapy p. 289
Isil Pasaoglu, Funda E Onmez
DOI:10.4103/ijo.IJO_732_18 We report an unusual case of hydroxychloroquine (HCQ) toxicity after only 2 months of starting the treatment. A 42-year-old woman presented with visual impairment. Her visual acuity was 20/20 in the right eye and 20/25 in the left eye. Ophthalmologic examination revealed a bull’s eye pattern in both eyes which was more prominent in the left eye. She had received HCQ therapy (400 mg/day) for 1 month, and had been taking 200 mg/day for 1 month for the treatment of rheumatoid arthritis. HCQ macular toxicity is rarely seen in short-term use, before 5 years, and to our knowledge, there is only one other case reported in the literature.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Quetiapine associated Central Serous Chorioretinopathy: Implicit role of serotonin and dopamine pathways p. 292
Manish Jain
DOI:10.4103/ijo.IJO_929_18 A 30-year-old insomniac, an off-label user of quetiapine, presented with blurring of central vision, eventually diagnosed as central serous chorioretinopathy. A potential association was suspected based on the drug’s actions on the autonomic nervous system. He showed improvement on drug withdrawal; then he unwittingly resumed quetiapine and had a recurrence. Possible underlying mechanisms that include alteration in choroidal perfusion through serotonin and dopamine receptors are discussed. Although retinal vein occlusions and pigment epithelial detachment have been described with quetiapine, to the author’s knowledge, this is the first case report of quetiapine-associated central serous chorioretinopathy.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Multicolor imaging findings in torpedo maculopathy p. 295
Ramesh Venkatesh, Bharathi Bavaharan, Naresh K Yadav
DOI:10.4103/ijo.IJO_1317_18 We describe the multicolor imaging findings in two cases of Torpedo maculopathy (TM). Multicolor imaging can be a useful tool in identifying the level of retinal and choroidal layer involvement in TM. This imaging modality further confirms the hypothesis that TM is a localized congenital abnormality of retinal pigment epithelium pigmentation which leads to outer retinal and inner choroidal degeneration.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Optical coherence tomography angiography features of retinitis post-rickettsial fever p. 297
Mahesh Shanmugam, Vinaya Kumar Konana, Rajesh Ramanjulu, KC Divyansh Mishra, Pradeep Sagar, Dilip Kumar
DOI:10.4103/ijo.IJO_799_18 The intraocular manifestations of rickettisial retinitis include retinal vasculitis, maculopathy, optic neuritis, and neurosensory detachment. Extensive leakage of dye on the fundus fluorescein angiography may obscure visualization in eyes with retinitis. We report the vascular changes in eyes with rickettsial retinitis and its response to treatment using optical coherence tomography angiography. The microvascular abnormalities we noted were, capillary drop out areas corresponding to retinitis patches, vascular loops, and pruning of vessels. The choriocapillary slabs showed signal void areas. Post-treatment there was vascular remodeling with decrease in non-perfused area, appearance of new vascular lateral branching, and appearance of collaterals.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png In vivo diagnosis of intraocular osseous metaplasia in neovascular age-related macular degeneration p. 300
Hibba Quhill, Stephen Stewart, Ian G Rennie
DOI:10.4103/ijo.IJO_1076_18 A 75-year-old man presented with deterioration of right eye vision for 6 months. He had no relevant medical history. Fundus examination revealed subretinal fluid, fibrosis, and subretinal hemorrhages. Ocular coherence tomography of the right macula illustrated an underlying subretinal lesion with internal lamellae, resembling trabecular bone elsewhere in the body. Bruch’s membrane was clearly intact beneath the lesion, indicating an extrachoroidal location. The lesion appeared highly reflective on B-scan ultrasonography, consistent with ossification. Although initially misdiagnosed as choroidal osteoma, this lesion represents in-vivo intraocular osseous metaplasia at the site of neovascular age-related macular degeneration. The authors believe that similar lesions may have been misdiagnosed as “atypical” osteoma caused by failure to identify their extrachoroidal location.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Do oblate eyeballs exist? A rare case of rhegmatogenous retinal detachment in an elliptical globe p. 302
M Dheepak Sundar, Prakhyat Roop, Atul Kumar, Rohan Chawla, Nasiq Hasan
DOI:10.4103/ijo.IJO_1150_18 A patient, being a moderate myope with an axial length of 24.71 mm, presented to us with a fresh rhegmatogenous retinal detachment and marked peripheral chorioretinal degeneration. Difficulty in maneuvering with the standard 23 gauge vitrectomy cutter, inability to identify the break due to poor peripheral contrast, inadequate laser uptake, and an unusual large silicon oil fill (7.3 ml) were a few findings raising suspicion. Postoperative ocular ultrasonography showed an oblate eyeball with a relatively longer oblique axis (26.1 mm) as compared to the axial length confirming our suspicion. Oblateness should be suspected when the chorioretinal degenerations are more marked in the periphery as compared to the posterior pole. Intraoperative difficulties should be kept in mind while operating such cases.
[ABSTRACT] [HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
LETTERS TO THE EDITOR Top
zoom.png Mr. Jack J. Kanski (1939-2019): A tribute p. 306
Suresh K Pandey, Vidushi Sharma
DOI:10.4103/ijo.IJO_37_19
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
Commentary: Pseudopestalotiopsis theae keratitis p. 307
Prashant Garg
DOI:10.4103/ijo.IJO_1490_18
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
Vitamin D supplementation in patients with xeroderma pigmentosum p. 308
Ashik Mohamed, Archana Bhargava, Sunita Chaurasia
DOI:10.4103/ijo.IJO_1319_18
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Changes in pattern electroretinogram after application of 0.01% atropine eye drops p. 309
Mihir Kothari, Deepak Bhat, Nitu Khadse, Rishika Jain, Vivek Rathod, Pallavi Aru
DOI:10.4103/ijo.IJO_989_18
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
zoom.png Comment on: Validating the pachychoroid disease spectrum using multimodal imaging p. 310
Jay U Sheth, Anantharaman Giridhar
DOI:10.4103/ijo.IJO_1460_18
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
Response to comment on: Validating the pachychoroid disease spectrum using multimodal imaging p. 312
Guruprasad Ayachit, Apoorva Ayachit, Harsha Nadgir, Shrinivas Joshi
DOI:10.4103/ijo.IJO_1870_18
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
Comment on: Bilateral combined central retinal artery and vein occlusion in a 3-year-old child with nephrotic syndrome p. 312
Anamika Dwivedi, Sujata Lakhtakia
DOI:10.4103/ijo.IJO_1633_18
[HTML Full text] [PDF] [Mobile Full text] [EPub] [Sword Plugin for Repository]Beta
Ophthalmology